



STATE OF WEST VIRGINIA



PUBLIC EMPLOYEES INSURANCE AGENCY

Fiscal Year 2024

Detailed Medical and Prescription Drugs Claim Trend Report

Report Date: October 2024

YOUR ACTUARIES FOR THE LONG-TERM!

TABLE OF CONTENTS

OVERVIEW	1
KEY FINDINGS	2
METHODOLOGY	7
TREND COMPARISON USING ALLOWED VERSUS PAID METHODOLOGY	9
TOP 5 CATEGORIES	9
SUMMARY	10
TOTAL NON-MEDICARE TREND	12
NON-MEDICARE 24-MONTH TREND	13
NON-MEDICARE 36-MONTH TREND	14
NON-MEDICARE 48-MONTH TREND	15
NON-MEDICARE 12-MONTH IN-STATE VERSUS OUT OF STATE CLAIMS	16
NON-MEDICARE PRESCRIPTION DRUGS TREND	17
Appendix A:	
Non-Medicare Medical Coverages – Cost Per Service, Utilization, Incurred PMPM Trends	
Appendix B	
Non-Medicare Prescription Drugs Coverages - Cost Per Service, Utilization, Incurred PMPM Trends	
Appendix C:	
Analysis of Top Forty Drugs Indicators	

West Virginia Public Employees Insurance Agency Report of Independent Actuary

Fiscal Year 2024 Detailed Medical & Prescription Drugs Claim Trend Report

OVERVIEW

Continuing Care Actuaries was engaged by the West Virginia Public Employees Insurance Agency (“PEIA”) to assist the Finance Board in monitoring the plan experience for fiscal year ending June 30, 2024 on a quarterly basis and the forecasting of Fiscal Years 2025 through 2029. This annual trend report to the Finance Board generally serves as the basis for projecting medical and drugs claims through Fiscal Year 2029 in the development of the Financial Plan to be approved by the PEIA Finance Board in December 2024. This report is intended for the sole use of the Finance Board and management team. Any other use requires written approval by Continuing Care Actuaries.

Continuing Care Actuaries has collected and reviewed the medical and drugs claims experience using Allowed Non-Medicare claims incurred and paid through June 2024. Effective July 1, 2012, West Virginia Retiree Health Benefit Trust Fund (“Trust Fund” or “RHBT”) had contracted with Humana to provide a Medicare Advantage Plan (“Humana MAPD”) benefit to Medicare-eligible retired employees and their Medicare-eligible dependents. Under this arrangement, Humana has assumed the financial risk of providing comprehensive medical and drugs. Non-Medicare retirees will continue enrollment in PEIA's Preferred Provider Benefit or the Managed Care Option.

While the majority of Medicare coverages are transferred to Humana, all newly eligible Medicare enrollees are initially covered by the RHBT on a secondary self-insured basis with Medicare being the primary coverage. These Medicare coverages are transferred in the following January from a self-insured secondary basis by RHBT to the Humana MAPD plan. While Continuing Care Actuaries monitors the cost trends of these Medicare coverages, we have not reviewed the Medicare claims experience in this report. This is due to the relatively small number of these Medicare coverages and the resulting lack of credibility of Medicare claims with RHBT as the secondary payor.

From July 1, 2000 to June 30, 2019, HealthSmart Holding Inc. (“HealthSmart”), was the administrator of the plan’s medical claims and has provided reports for both medical and prescription drugs claims. Effective July 1, 2019, administration was assumed by United Medical Resources Inc. (“UMR”). The analysis utilized claim data supplied from UMR as a primary source of claims data for this report and PEIA has separately provided enrollment information. Data was processed and provided to Continuing Care Actuaries by PEIA’s data warehouse manager Mike Madalena.

Trends were developed by category for the 24-month, 36-month and 48-month credible periods ending June 2024. The analysis for medical claims do not include incurred claims for the months after June 2024. The claim experience for the months after June 2024 is largely non-credible as substantial reserves as part of the projected monthly incurred amount. The claim information supplied by UMR for the purposes of this analysis was compared to PEIA’s general ledger system to ensure accuracy of aggregate reporting. Additionally, in an effort to assure accuracy the claim

information provided by UMR used in this analysis was reconciled and balanced to the PEIA general ledger amounts as of June 2024.

KEY FINDINGS - MEDICAL

- The 24-month, 36-month and 48-month methodologies had various utilization and unit cost trends. Long-term methodologies are most likely to produce accurate future trends that will allow PEIA to develop a financially solvent Financial Plan over the required five-year projection period. The overall medical trend increased from 5.5% in last year's analysis to 20.0% in Fiscal Year 2024 using a 24-month study period, due to increases in the West Virginia hospital reimbursements fee schedules and multiple large claims payment made in FY 2024. Using the 24-month analysis, PEIA experienced a 7.5% trend in utilization and a 11.6% trend in unit cost, resulting in an aggregate trend of 20.0%. The 36-month method resulted in a lower trend of 12.4% and the 48-month method resulted in a lower trend of 11.2%.

The results below illustrate the 24-month trend calculated since Fiscal Year 2002.

West Virginia PEIA Non-Medicare Total 24-Month Trend Analysis-Allowed Claims			
	<u>Utilization</u>	<u>Cost/Service</u>	<u>Total Trend</u>
2002	4.1%	3.6%	7.8%
2003	9.8%	-3.0%	6.5%
2004	11.7%	-6.8%	4.0%
2005	2.8%	-1.1%	1.7%
2006	2.9%	1.0%	4.0%
2007	7.2%	-2.0%	5.1%
2008	2.9%	3.9%	6.9%
2009	2.5%	2.6%	5.1%
2010	2.5%	1.8%	4.4%
2011	4.2%	3.5%	7.8%
2012	5.1%	0.1%	5.3%
2013	2.6%	-1.6%	0.9%
2014	-0.4%	4.5%	4.1%
2015	0.7%	5.6%	6.3%
2016	8.6%	-0.7%	7.9%
2017	3.9%	-1.1%	2.8%
2018	4.4%	2.4%	6.9%
2019	5.5%	3.0%	8.6%
2020	3.2%	1.6%	4.8%
2021	3.2%	7.3%	10.7%
2022	4.5%	4.3%	9.0%
2023	-1.9%	7.5%	5.5%
2024	7.5%	11.6%	20.0%

- In addition to studying trends on a 24, 36, and 48-month basis, CCA also looked at the trends for claims In-State and Out-of-State. Out-of-State claims were further divided into Border Counties ("OOS BC") and Non-Border Counties ("OOS NBC") as there are different cost sharing provisions in the PPB plans for services provided in Out-of-State Border Counties and Non-Border Counties.

- Overall PEIA and RHBT Fiscal Year 2024 24-month detail trends are summarized below. Note that these trends have not been adjusted for any changes in the plan benefit design and drug rebates are not included in this analysis:

Fiscal Year 2024 Claim Type	Medical	Gross Drugs
PEIA – Active Local	18.0%	50.0%
<u>PEIA – State</u>	<u>20.5%</u>	<u>47.8%</u>
PEIA – Total	20.0%	48.2%
RHBT – Non-Medicare	2.8%	26.3%
Grand Total	18.6%	46.3%

- In the 12-month analysis, the tables below show the comparison of this year's weight and last year's weight by the number of visits and the total allowed cost, between In-State, OOS NBC and OOS BC, and by the four categories (HI, HO, PS and O). Due to increases in the WV hospital reimbursements fee schedules, the weight for the total allowed cost has shifted significantly from OOS NBC and OOS BC to In-State under Hospital Inpatient, a 10.9% difference from last year to this year.

12 Month Summary (FY 2024 Weight)

	<u>Number of Visits</u>			<u>Total Allowed Cost</u>		
	<u>In-State %</u>	<u>OOS NBC %</u>	<u>OOS BC %</u>	<u>In-State %</u>	<u>OOS NBC %</u>	<u>OOS BC %</u>
Hospital Inpatient	82.8%	11.9%	5.3%	70.5%	24.3%	5.2%
Hospital Outpatient	93.1%	3.7%	3.2%	75.9%	12.9%	11.2%
Physician Services	85.3%	10.8%	3.8%	81.1%	14.3%	4.6%
<u>Other Services</u>	<u>77.1%</u>	<u>19.4%</u>	<u>3.6%</u>	<u>78.2%</u>	<u>19.4%</u>	<u>2.4%</u>
Total	86.5%	9.8%	3.7%	76.7%	16.3%	7.0%

12 Month Summary (FY 2023 Weight)

	<u>Number of Visits</u>			<u>Total Allowed Cost</u>		
	<u>In-State %</u>	<u>OOS NBC %</u>	<u>OOS BC %</u>	<u>In-State %</u>	<u>OOS NBC %</u>	<u>OOS BC %</u>
Hospital Inpatient	83.7%	11.7%	4.6%	59.6%	31.8%	8.6%
Hospital Outpatient	92.2%	4.7%	3.1%	75.8%	13.3%	10.9%
Physician Services	85.5%	10.7%	3.7%	81.9%	13.8%	4.4%
<u>Other Services</u>	<u>78.0%</u>	<u>18.2%</u>	<u>3.8%</u>	<u>76.4%</u>	<u>20.2%</u>	<u>3.4%</u>
Total	86.4%	9.9%	3.7%	76.1%	16.5%	7.4%

12 Month Summary (FY 2024 vs FY 2023 Difference)

	<u>Number of Visits</u>			<u>Total Allowed Cost</u>		
	<u>In-State %</u>	<u>OOS NBC %</u>	<u>OOS BC %</u>	<u>In-State %</u>	<u>OOS NBC %</u>	<u>OOS BC %</u>
Hospital Inpatient	-0.9%	0.2%	0.7%	10.9%	-7.5%	-3.5%
Hospital Outpatient	0.9%	-1.0%	0.0%	0.1%	-0.4%	0.3%
Physician Services	-0.2%	0.1%	0.1%	-0.7%	0.5%	0.2%
<u>Other Services</u>	<u>-0.9%</u>	<u>1.1%</u>	<u>-0.2%</u>	<u>1.8%</u>	<u>-0.8%</u>	<u>-1.0%</u>
Total	0.1%	-0.2%	0.1%	0.6%	-0.2%	-0.5%


- In the 24-month analysis, In-State services have experienced higher trends than OOS NBC and OOS BC services for Non-Medicare coverages in two out of four categories (HI and O, not HO and PS). A comparison of Non-Medicare medical trends for In-State claims versus OOS NBC claims versus OOS BC claims over the 24-month period analysis reveals an aggregate In-State trend of 24.5%, an aggregate OOS NBC trend of 5.8%, and an aggregate OOS BC trend of 18.2%.

The OOS NBC utilization trend has been lower compared to In-State and OOS BC trends, while the OOS NBC cost per service trend has been higher compared to In-State and OOS BC trends. The In-State utilization trend for Non-Medicare was 8.8%, while the OOS NBC trend was -9.1% and the OOS BC trend was 13.0%. The In-State cost per service trend for Non-Medicare was 14.4%, while the OOS NBC trend was 16.4%, and the OOS BC trend was 4.6%.

Within the In-State medical categories, the 3 highest trend subcategories were observed for Hospital Inpatient's Maternity, Hospital Inpatient's Medical / Surgical, and Hospital Inpatient's Psychiatric / Substance Abuse categories. These categories experienced high trends of 65.3%, 92.2% and 150.2%, respectively.

- Using the 24-month analysis, Hospital Inpatient services ("HI") represent 19.9% of all medical services and experienced a total trend of 56.5%. The overall trend was the product of a 7.3% increase in utilization and a 45.8% increase in unit cost. In-State HI claims had a 94.7% overall trend, while OOS NBC HI claims experienced a 5.2% overall trend, and OOS BC HI claims experienced a 18.2% overall trend.
- Using the 24-month analysis, Hospital Outpatient services ("HO") represent 35.1% of all medical services and experienced the least favorable trend of the broader claim categories with a total trend of 19.8%. The overall trend was the product of a 18.1% increase in utilization and a 1.5% increase in unit cost. In-State HO claims had a 20.8% overall trend, while OOS NBC HO claims experienced an 9.1% overall trend, and OOS BC HO claims experienced an 23.7% overall trend.
- Using the 24-month analysis, Physician Services ("PS") represent 43.8% of all medical services and experienced a total trend of 3.8%. The overall trend was the product of a -0.4% decrease in utilization of these services and an 4.2% increase in unit cost. In-State PS claims had a 3.2% overall trend, while OOS NBC PS claims experienced a 3.7% overall trend, and OOS BC PS claims experienced an 8.0% overall trend.
- Using the 24-month analysis, Other services ("O"), which are services that are principally Ambulance and Durable Medical Services, represent 1.2% of all medical services and experienced a total trend of 5.1%. The overall trend was the product of a -6.5% decrease in utilization of these services and a 12.4% increase in unit cost. In-State O claims showed a 9.0% overall trend, while OOS NBC O claims experienced a -4.9% overall trend, and OOS BC O claims experienced a -16.5% overall trend.
- As noted above, the OOS NBC trends were generally more favorable than the In-State trends and the OOS BC trends. This is similar to last year's report that the OOS NBC trends were more favorable.

- In the 24 and 36-month analysis, Hospital Inpatient trends in all locations were substantially higher than the overall medical trend in this year's report. Conversely, Hospital Inpatient trends were substantially lower than the overall medical trend in last year's report.
- A component of the cost per service trend for hospital inpatient is the length of stay, or intensity. The chart below shows the average length of stay by number of days over the last four years. Over the 48-month analysis, the intensity for Non-Medicare hospital stays has an annual trend of -4.3%, which is comparable to -1.1% last year. The historical data is illustrated in the chart below.



The table below presents the overall Non-Medicare Hospital Inpatient trend showing the three components of visits, days per visit, and cost per day.

West Virginia PEIA Non-Medicare Hospital Inpatient Trend Analysis			
	<u>24-Month</u>	<u>36-Month</u>	<u>48-Month</u>
Visits	-0.9%	-3.9%	-3.9%
Intensity	-7.8%	-9.2%	-4.3%
<u>Cost/Day</u>	<u>71.3%</u>	<u>49.3%</u>	<u>33.9%</u>
Total	56.5%	30.2%	23.1%

Continuing Care Actuaries has included an additional analysis of utilization and cost on an incurred basis over the last 12 months. This analysis can be found on Page 16 and analyzes the distribution of services based on services provided in West Virginia and services provided elsewhere.

In the 12-month period ending June 2024, 86.5% of medical services were provided in the State of West Virginia, 9.8% of services were provided OOS NBC, and 3.7% of services were provided OOS BC. From a cost perspective, 76.7% of allowed charges were incurred In-State, 16.3% of allowed charges were provided OOS NBC, and 7.0% of allowed charges were provided OOS BC, illustrating the higher cost and intensity of the out-of-state and border county services.

By major medical category, 82.8% of Hospital Inpatient services were provided in the State of West Virginia representing 70.5% of the total allowed charges for Hospital Inpatient. Conversely, 11.9% of Hospital Inpatient services were provided OOS NBC and those charges represented 24.3% of the total allowed charges for Hospital Inpatient. In addition, 5.3% of Hospital Inpatient services were provided OOS BC and those charges represented 5.2% of the total allowed charges for Hospital Inpatient.

By major medical category, 93.1% of Hospital Outpatient services were provided in the State of West Virginia representing 75.9% of the total allowed charges for Hospital Outpatient. Conversely, 3.7% of Hospital Outpatient services were provided OOS NBC and those charges represented 12.9% of the total allowed charges for Hospital Outpatient. In addition, 3.2% of Hospital Outpatient services were provided OOS BC and those charges represented 11.2% of the total allowed charges for Hospital Outpatient.

By major medical category, 85.3% of Physician Services were provided in the State of West Virginia representing 81.1% of the total allowed charges for Physician Services. Conversely, 10.8% of Physician Services were provided OOS NBC and those charges represented 14.3% of the total allowed charges for Physician Services. In addition, 3.8% of Physician Services were provided OOS BC and those charges represented 4.6% of the total allowed charges for Physician Services.

By major medical category, 77.1% of Other Services were provided in the State of West Virginia representing 78.2% of the total allowed charges for Other Services. Conversely, 19.4% of Other Services were provided OOS NBC and those charges represented 19.4% of the total allowed charges for Other Services. In addition, 3.6% of Other Services were provided OOS BC and those charges represented 2.4% of the total allowed charges for Other Services.

KEY FINDINGS - DRUGS

Overall, gross prescription drugs trends for Non-Medicare coverages have increased significantly compared to 5.3% last year. Using the 24-month analysis, there was a 5.0% utilization increase and a 41.2% prescription cost increase, resulting in an aggregate trend of 48.2% when adjusting for membership exposure. The 24-month overall trend is higher than the 36-month trend of 12.2% and the 48-month trend of 10.8%.

West Virginia PEIA Prescription Drugs Total 24-Month Trend Analysis-Allowed Claims			
	<u>Utilization</u>	<u>Cost/Prescription</u>	<u>Total Trend</u>
FY 2024	5.0%	41.2%	48.2%

The large one year rise in the allowed drug trend is likely due to the increased utilization of high cost GLP-1 drugs. PEIA has put new policies in place to limit GLP-1 drugs that are prescribed for weight loss alone.

METHODOLOGY

UMR provided allowed and paid claim information for Non-Medicare and Medicare eligibility from July 2001 through August 2024. This data set was analyzed for Non-Medicare claims that were incurred from July 2020 through June 2024 in the 48-month credible period. The claim data was consolidated into 23 categories for Hospital Inpatient, Hospital Outpatient, Physician Services, and Other. In addition, claim experience was analyzed based on the state of service as defined by UMR. UMR provides the information based on the location that the service was performed, rather than the billing location of the provider. Continuing Care Actuaries verified that the UMR information balanced in total to previously produced claim lag reports that PEIA personnel have balanced to the PEIA ledger accounts.

The trend analysis includes assumptions with respect to the completeness of the claim information to reflect and adjust for unreported claims. There was no adjustment to reflect the various reductions and changes in benefit design as affected by the Finance Board over the analysis period, such as an increase in hospital inpatient reimbursement rates. In developing aggregate claim trends, individual claim categories were weighted by claims paid for each category over the last 24, 36 and 48 months, respectively. The following charts summarize the amount of allowed dollars by category for each paid fiscal year.

The calculated trends for utilization, unit cost and in aggregate were based on the least squares methodology in defining the regression trend line. These trend lines were manually adjusted when the results appeared to be less credible.

Consistent with prior reports, the trends published in this report for Non-Medicare medical claims are based on the allowed amount in order to neutralize the impact of deductibles and copayments that have a varying impact on paid amounts in various months of the year. Paid claim trends are typically higher over the study period when cost-sharing provisions of the plan do not increase in the most recent Plan Year.

A summary of the annual Non-Medicare data provided by UMR by Hospital Inpatient (HI), Hospital Outpatient (HO), Physician Services (PS), and Other Services (O) is detailed below.

<u>Non-Medicare Claims</u>	<u>FY2021</u>	<u>FY2022</u>	<u>FY2023</u>	<u>FY2024</u>
Hospital Inpatient	\$121,492,383	\$123,339,398	\$122,709,218	\$202,677,934
Hospital Outpatient	228,700,978	248,383,349	263,905,572	290,675,202
Physician Services	298,218,144	320,673,123	323,952,985	324,444,471
Other Services	26,849,533	26,392,414	27,788,296	27,618,466
Total	\$675,261,039	\$718,788,285	\$738,356,070	\$845,416,072

Certain categories in the data provided by UMR were consolidated to produce the following summary table for Non-Medicare claims.

<u>Non-Medicare Claims</u>	<u>FY2021</u>	<u>FY2022</u>	<u>FY2023</u>	<u>FY2024</u>
HI Maternity	\$9,364,069	\$13,155,706	\$9,923,983	\$20,877,408
HI Medical/Surgical	108,713,948	106,535,835	108,834,986	172,849,862
HI Psychiatric/Substance Abuse	3,414,367	3,647,857	3,950,249	8,950,663
HO Emergency Room	31,588,339	35,629,865	39,279,762	40,773,414
HO Medical/Surgical	105,944,593	115,206,649	127,951,265	144,030,794
HO Other Services	89,101,905	94,412,745	92,806,088	103,561,322
HO Psychiatric/Substance Abuse	2,066,141	3,134,090	3,868,457	2,309,673
PS Anesthesia	14,574,192	14,320,756	14,149,816	13,679,239
PS Chemotherapy/Radiation	2,145,269	2,491,248	1,998,987	1,899,554
PS Emergency Room	5,299,981	5,649,808	5,781,495	5,922,645
PS Immunizations/Allergy	9,028,186	8,758,913	8,882,046	8,209,720
PS Inpatient Surgery	7,356,918	6,168,356	6,709,830	5,738,156
PS Inpatient Visits	7,938,575	8,386,671	7,257,455	7,932,245
PS Lab & Pathology	12,732,213	14,794,728	15,117,167	16,347,046
PS Maternity	8,925,760	8,889,694	8,760,243	8,203,353
PS Office Visits	68,327,697	79,460,827	81,653,330	79,802,319
PS Other Services	105,038,383	111,794,636	110,275,558	112,235,178
PS Outpatient Surgery	24,659,538	24,444,723	25,259,089	24,770,238
PS Psychiatric/Substance Abuse	20,111,793	23,012,275	25,451,151	27,644,287
PS Radiology	12,079,641	12,500,488	12,656,819	12,060,491
PS Therapy/Rehab	16,803,787	16,860,709	18,194,778	17,768,502
O Ambulance	5,038,523	5,055,073	5,217,972	4,929,987
O Durable Medical Equipment	5,007,223	4,476,633	4,375,546	4,919,976

TREND COMPARISON USING ALLOWED VERSUS PAID METHODOLOGY

The trend analysis has been developed throughout the report on an allowed basis for Non-Medicare claims to neutralize the impact of deductibles and co-payments that have a varying impact on paid amounts depending on the month of the year.

We have examined the trends utilizing paid claims as opposed to allowed claims. The following table summarizes the trends on a paid basis for the Fiscal Years 2021 through 2024 and on an allowed basis for Non-Medicare medical claims. This exercise is important since interim monthly trend updates provided to PEIA throughout the year are based on paid claims.

West Virginia PEIA Non-Medicare Medical Total Trend Analysis		
	<u>Paid Basis</u>	<u>Allowed Basis</u>
24-Month Trend	26.7%	20.0%
36-Month Trend	16.6%	12.4%
48-Month Trend	13.4%	11.2%

It is noteworthy that the paid trends are greater than the allowed trends in each of the time periods analyzed above. This is a common phenomenon that occurs when there are little to no benefit changes during a given time period.

TOP 5 CATEGORIES

The following tables give detail on the top 5 increases by utilization, cost per service, and cost per capita using the 24-month analysis. Notably, HI-Psychiatric / Substance Abuse experienced the highest increase in utilization; HI- Maternity experienced the highest increase in cost per service; and HI-Psychiatric / Substance Abuse experienced the highest increase in cost per capita.

Top 5 Highest Percentage in Utilization Increases			
	2023 Average	2024 Average	Top 5
<u>Category</u>	<u>Utilization</u>	<u>Utilization</u>	<u>Highest %</u>
HI-Psychiatric / Substance Abuse	0.00049	0.00084	72.8%
HO-Medical / Surgical	0.09705	0.12373	27.5%
HO-Psychiatric / Substance Abuse	0.00514	0.00623	21.3%
HO- Other Services	0.14255	0.15883	11.4%
PS-Psychiatric / Substance Abuse	0.12162	0.13366	9.9%

Top 5 Highest Percentage in Cost / Service Increases			
	2023 Average	2024 Average	Top 5
<u>Category</u>	<u>Cost / Service</u>	<u>Cost / Service</u>	<u>Highest %</u>
HI-Maternity	\$2,366.14	\$3,853.25	62.8%
HI-Medical / Surgical	11,939.30	17,282.46	44.8%
HI-Psychiatric / Substance Abuse	4,571.66	5,894.83	28.9%
PS-Anesthesia	201.58	255.62	26.8%
O- Durable Medical Equipment	139.53	175.33	25.7%

Top 5 Highest Percentage in Cost / Capita Increases			
	2023 Average	2024 Average	Top 5
<u>Category</u>	<u>Cost / Capita</u>	<u>Cost / Capita</u>	<u>Highest %</u>
HI-Psychiatric / Substance Abuse	\$2.23	\$4.96	122.8%
HI-Maternity	6.55	10.77	64.4%
HI-Medical / Surgical	61.88	94.08	52.0%
HO-Medical / Surgical	66.68	83.25	24.9%
HO- Other Services	49.60	58.38	17.7%

SUMMARY

The following tables and sections summarize the information and findings of the trend analysis. The tables and charts on the next several pages include separate analysis of utilization and unit cost trends for Non-Medicare coverages. The charts show the breakdown between the different study periods and for In-State, OOS NBC, and OOS BC.

Recent experience has shown that the Allowed Non-Medicare medical claim trends are higher than the current trend assumption of 8.0% for FY 2025. Additionally, the 24-Month trend has reflected a higher 20.0% trend for medical, while the 36-month trend is 12.4% and the 48-month trend is 11.2%. CCA believes that it is appropriate to retain the FY 2025 medical claim trend assumption for Non-Medicare medical at 8.0%, given the long-term trend experience and the difference in the Allowed trend calculated in this report and the Paid trends applied in the Financial Plan projections.

Additionally, recent experience has shown that Non-Medicare gross drugs claim trends are higher than the current trend assumption of 15.0% for FY 2025. The 24-Month trend has reflected a 48.2% trend for drugs, before rebates. It should be noted that the 36-month trend is 12.2% and the 48-month trend is 10.8%. CCA believes that it is appropriate to retain the FY 2025 prescription drugs claim trend assumption for Non-Medicare prescription drugs at 15.0%. This approximates the 48-month trend experience and factors in the difference in the level of Paid trend versus Allowed trends.

The update of the trend assumptions for FY 2025 is shown below.

Claim Type	Fiscal Year 2025 Trends		
	Previous Assumption	Updated Assumption	Change
Non-Medicare – Medical	8.0%	8.0%	0.0%
Non-Medicare – Gross Prescription Drugs	15.0%	15.0%	0.0%

In the past, claim trends for the financial plan included a 0.5% margin in future years. CCA has assumed the medical claim trends for the financial projection will increase by 0.5% in FY 2026 and in each successive fiscal year. Gross prescription drugs claim trends are assumed to increase 0.5% in FY 2026 and thereafter. Additionally, drug rebates have been trending at approximately 9% over the last two years. However, they were almost flat in FY2024. As a result, CCA has separated net drugs in the financial plan into gross drugs and drug rebate amounts. Drug rebates trends are set at 5% in the financial plan.

We will continue to monitor the claim trend experience and incorporate changes as necessary throughout the fiscal year based on the relatively volatile nature of recent trend experience at PEIA.

Respectfully,



Dave Bond, F.S.A., M.A.A.A.

Managing Partner



Chris Borcik, F.S.A., M.A.A.A.

Principal

West Virginia PEIA Non-Medicare Medical Total

Study Period of July 2020 to June 2024

(Allowed Claims)

Trends Summary - Excludes Drugs

	Utilization	24 Month Trends Summary			Weight	Utilization	36 Month Trends Summary			Weight	Utilization	48 Month Trends Summary			Weight
		Cost / Service	Total Trend				Cost / Service	Total Trend				Cost / Service	Total Trend		
HOSPITAL INPATIENT															
Maternity	0.9%	62.8%	64.4%	1.9%		-1.1%	35.3%	33.8%	1.9%		-0.3%	31.9%	31.5%	1.7%	
Medical / Surgical	5.0%	44.8%	52.0%	17.2%		1.1%	26.4%	27.8%	16.5%		-1.1%	22.5%	21.2%	16.4%	
Psychiatric / Substance Abuse	72.8%	28.9%	122.8%	0.8%		44.3%	21.3%	75.0%	0.7%		23.4%	22.1%	50.6%	0.7%	
TOTAL	7.3%	45.8%	56.5%	19.9%		2.5%	27.1%	30.2%	19.0%		-0.2%	23.4%	23.1%	18.8%	
HOSPITAL OUTPATIENT															
Emergency Room	2.0%	6.5%	8.7%	5.1%		1.2%	8.7%	10.0%	5.0%		3.6%	7.8%	11.7%	5.0%	
Medical / Surgical	27.5%	-2.1%	24.9%	17.2%		16.6%	2.2%	19.1%	16.8%		13.3%	2.4%	16.1%	16.6%	
Other Services	11.4%	5.6%	17.7%	12.4%		1.4%	6.7%	8.1%	12.6%		0.9%	6.3%	7.3%	12.8%	
Psychiatric / Substance Abuse	21.3%	-38.7%	-25.7%	0.4%		17.8%	-22.9%	-9.2%	0.4%		19.8%	-8.1%	10.1%	0.4%	
TOTAL	18.1%	1.5%	19.8%	35.1%		8.9%	4.4%	13.7%	34.9%		7.4%	4.5%	12.3%	34.7%	
PHYSICIAN SERVICES															
Anesthesia	-18.0%	26.8%	3.9%	1.8%		-23.8%	33.1%	1.4%	1.8%		-14.9%	19.2%	1.4%	1.9%	
Chemotherapy / Radiation	-4.8%	0.7%	-4.1%	0.2%		-0.9%	-9.8%	-10.6%	0.3%		3.5%	-7.6%	-4.4%	0.3%	
Emergency Room	-2.0%	7.8%	5.7%	0.7%		1.6%	3.4%	5.0%	0.8%		4.1%	1.7%	5.8%	0.8%	
Immunizations / Injections / Allergy	-21.3%	9.9%	-13.5%	1.1%		-10.7%	6.3%	-5.0%	1.1%		-7.1%	4.1%	-3.2%	1.2%	
Inpatient Surgery	-1.9%	-4.0%	-5.8%	0.8%		-2.1%	3.0%	0.8%	0.8%		-3.9%	0.8%	-3.1%	0.9%	
Inpatient Visits	4.1%	4.6%	8.8%	1.0%		0.3%	-1.0%	-0.7%	1.0%		1.7%	-0.9%	0.8%	1.1%	
Lab & Pathology	-3.7%	13.8%	9.7%	2.0%		-7.8%	15.4%	6.4%	2.0%		-0.6%	11.2%	10.5%	2.0%	
Maternity	6.1%	-8.1%	-2.5%	1.1%		4.4%	-5.1%	-0.9%	1.1%		4.6%	-4.3%	0.1%	1.2%	
Office Visits	2.8%	-0.1%	2.7%	10.3%		0.1%	3.1%	3.1%	10.6%		3.3%	4.2%	7.6%	10.5%	
Other Services	-4.1%	6.3%	2.0%	14.2%		-6.5%	9.3%	2.2%	14.7%		-5.3%	9.7%	3.9%	14.9%	
Outpatient Surgery	5.3%	1.6%	6.9%	3.2%		8.4%	-2.9%	5.2%	3.3%		10.1%	-6.7%	2.7%	3.4%	
Psychiatric / Substance Abuse	9.9%	4.6%	15.0%	3.4%		9.1%	4.2%	13.6%	3.3%		7.7%	6.4%	14.6%	3.3%	
Radiology	1.3%	-2.5%	-1.2%	1.6%		-0.6%	1.6%	1.0%	1.6%		2.0%	0.4%	2.4%	1.7%	
Therapies	7.5%	-3.5%	3.7%	2.3%		6.3%	-0.1%	6.2%	2.3%		4.0%	1.2%	5.3%	2.4%	
TOTAL	-0.4%	4.2%	3.8%	43.8%		-2.0%	6.0%	3.9%	44.8%		-0.1%	5.5%	5.4%	45.2%	
OTHER															
Ambulance	-5.8%	0.2%	-5.6%	0.6%		6.3%	-7.1%	-1.2%	0.7%		6.6%	-5.0%	1.3%	0.7%	
Appliances (DME)	-7.2%	25.7%	16.6%	0.6%		-6.6%	16.8%	9.1%	0.6%		-0.9%	4.3%	3.4%	0.6%	
TOTAL	-6.5%	12.4%	5.1%	1.2%		0.2%	4.3%	4.4%	1.3%		3.0%	-0.5%	2.5%	1.3%	
GRAND TOTAL	7.5%	11.6%	20.0%	100.0%		2.7%	9.5%	12.4%	100.0%		2.6%	8.4%	11.2%	100.0%	

West Virginia PEIA Non-Medicare Medical Total
Study Period of July 2022 to June 2024
(Allowed Claims)

24 Month Trends Summary - Excludes Drugs

	In-State			OOS NBC			OOS BC			Total			In-State	OOS NBC	OOS BC	Total
	Utilization	Cost / Service	Total Trend	Utilization	Cost / Service	Total Trend	Utilization	Cost / Service	Total Trend	Utilization	Cost / Service	Total Trend	Weight	Weight	Weight	Weight
HOSPITAL INPATIENT																
Maternity	-2.3%	69.2%	65.3%	14.3%	35.4%	54.7%	50.1%	-5.4%	42.0%	0.9%	62.8%	64.4%	1.8%	1.8%	2.3%	1.9%
Medical / Surgical	8.1%	77.9%	92.2%	-10.7%	13.9%	1.8%	8.4%	5.1%	13.9%	5.0%	44.8%	52.0%	14.0%	32.5%	15.0%	17.2%
Psychiatric / Substance Abuse	106.8%	21.0%	150.2%	13.1%	32.4%	49.7%	3.3%	15.1%	18.9%	72.8%	28.9%	122.8%	0.8%	0.7%	0.3%	0.8%
TOTAL	11.9%	74.1%	94.7%	-8.9%	15.4%	5.2%	13.7%	3.9%	18.2%	7.3%	45.8%	56.5%	16.6%	35.0%	17.7%	19.9%
HOSPITAL OUTPATIENT																
Emergency Room	3.9%	6.3%	10.4%	-24.8%	21.3%	-8.8%	3.4%	4.3%	7.8%	2.0%	6.5%	8.7%	4.6%	3.5%	14.1%	5.1%
Medical / Surgical	29.6%	-5.1%	22.9%	-10.1%	31.9%	18.6%	23.6%	18.7%	46.7%	27.5%	-2.1%	24.9%	17.2%	13.9%	25.1%	17.2%
Other Services	12.3%	8.4%	21.7%	-14.5%	18.6%	1.4%	22.3%	-18.0%	0.3%	11.4%	5.6%	17.7%	12.8%	9.6%	14.8%	12.4%
Psychiatric / Substance Abuse	27.5%	-44.4%	-29.1%	-38.8%	126.0%	38.2%	12.6%	1.6%	14.3%	21.3%	-38.7%	-25.7%	0.5%	0.2%	0.2%	0.4%
TOTAL	19.9%	0.8%	20.8%	-13.8%	26.5%	9.1%	17.9%	4.9%	23.7%	18.1%	1.5%	19.8%	35.0%	27.2%	54.2%	35.1%
PHYSICIAN SERVICES																
Anesthesia	-19.7%	22.8%	-1.3%	-12.9%	37.6%	19.9%	11.1%	9.4%	21.6%	-18.0%	26.8%	3.9%	1.7%	2.1%	1.6%	1.8%
Chemotherapy / Radiation	-5.5%	-6.5%	-11.6%	9.9%	28.9%	41.6%	-5.1%	2.2%	-3.0%	-4.8%	0.7%	-4.1%	0.2%	0.2%	0.3%	0.2%
Emergency Room	1.1%	4.3%	5.4%	-25.2%	40.3%	4.9%	0.6%	15.5%	16.2%	-2.0%	7.8%	5.7%	0.8%	0.6%	0.9%	0.7%
Immunizations / Injections / Allergy	-20.6%	10.2%	-12.5%	-36.3%	16.7%	-25.7%	-9.4%	-5.7%	-14.5%	-21.3%	9.9%	-13.5%	1.3%	0.4%	0.8%	1.1%
Inpatient Surgery	-2.4%	-5.5%	-7.7%	2.4%	-3.7%	-1.4%	-11.4%	3.3%	-8.5%	-1.9%	-4.0%	-5.8%	0.7%	1.3%	0.4%	0.8%
Inpatient Visits	-0.6%	-2.8%	-3.4%	24.0%	22.2%	51.5%	-20.7%	18.5%	-6.0%	4.1%	4.6%	8.8%	0.9%	1.4%	0.5%	1.0%
Lab & Pathology	-7.0%	19.0%	10.6%	1.3%	7.3%	8.8%	7.5%	3.6%	11.3%	-3.7%	13.8%	9.7%	1.2%	6.1%	0.7%	2.0%
Maternity	-4.4%	-2.4%	-6.7%	26.7%	-6.9%	17.9%	35.9%	-24.7%	2.4%	6.1%	-8.1%	-2.5%	1.1%	1.3%	0.5%	1.1%
Office Visits	3.0%	-0.8%	2.2%	0.7%	8.0%	8.8%	0.6%	3.7%	4.3%	2.8%	-0.1%	2.7%	12.2%	3.9%	5.6%	10.3%
Other Services	-3.2%	6.0%	2.6%	-20.5%	12.1%	-11.0%	-1.4%	11.4%	9.9%	-4.1%	6.3%	2.0%	14.7%	13.8%	9.9%	14.2%
Outpatient Surgery	3.3%	2.8%	6.2%	17.3%	-5.3%	11.1%	27.8%	-13.6%	10.4%	5.3%	1.6%	6.9%	3.5%	2.1%	2.7%	3.2%
Psychiatric / Substance Abuse	11.2%	4.4%	16.1%	-5.3%	1.8%	-3.6%	8.0%	8.9%	17.6%	9.9%	4.6%	15.0%	4.1%	1.2%	0.8%	3.4%
Radiology	1.0%	-4.1%	-3.2%	4.5%	3.6%	8.2%	0.5%	-1.5%	-1.0%	1.3%	-2.5%	-1.2%	1.6%	1.4%	1.9%	1.6%
Therapies	7.5%	-3.7%	3.5%	19.1%	-1.6%	17.2%	-0.5%	2.2%	1.7%	7.5%	-3.5%	3.7%	2.9%	0.3%	0.9%	2.3%
TOTAL	-0.1%	3.3%	3.2%	-5.9%	10.3%	3.7%	3.2%	4.7%	8.0%	-0.4%	4.2%	3.8%	47.1%	36.2%	27.6%	43.8%
OTHER																
Ambulance	-5.4%	2.2%	-3.3%	-6.4%	-5.6%	-11.6%	-11.5%	-13.7%	-23.6%	-5.8%	0.2%	-5.6%	0.7%	0.7%	0.3%	0.6%
Appliances (DME)	-7.7%	32.8%	22.5%	-4.3%	5.8%	1.3%	-12.0%	9.5%	-3.7%	-7.2%	25.7%	16.6%	0.6%	0.8%	0.2%	0.6%
TOTAL	-6.5%	16.6%	9.0%	-5.3%	0.4%	-4.9%	-11.6%	-5.5%	-16.5%	-6.5%	12.4%	5.1%	1.3%	1.5%	0.5%	1.2%
GRAND TOTAL	8.8%	14.4%	24.5%	-9.1%	16.4%	5.8%	13.0%	4.6%	18.2%	7.5%	11.6%	20.0%	100.0%	100.0%	100.0%	100.0%

**West Virginia PEIA Non-Medicare Medical Total
Study Period of July 2021 to June 2024
(Allowed Claims)**

36 Month Trends Summary - Excludes Drugs

	In-State			OOS NBC			OOS BC			Total			In-State	OOS NBC	OOS BC	Total
	Utilization	Cost / Service	Total Trend	Utilization	Cost / Service	Total Trend	Utilization	Cost / Service	Total Trend	Utilization	Cost / Service	Total Trend	Weight	Weight	Weight	Weight
HOSPITAL INPATIENT																
Maternity	-0.7%	50.7%	49.6%	-20.4%	37.3%	9.3%	15.8%	0.5%	16.4%	-1.1%	35.3%	33.8%	1.7%	2.3%	2.3%	1.9%
Medical / Surgical	2.0%	52.0%	55.1%	-2.9%	6.3%	3.2%	-0.9%	5.6%	4.7%	1.1%	26.4%	27.8%	13.1%	30.6%	17.1%	16.5%
Psychiatric / Substance Abuse	60.7%	20.6%	93.9%	18.7%	25.5%	48.9%	-13.3%	10.3%	-4.3%	44.3%	21.3%	75.0%	0.7%	0.7%	0.4%	0.7%
TOTAL	4.5%	50.4%	57.2%	-3.7%	8.8%	4.8%	0.9%	5.1%	6.0%	2.5%	27.1%	30.2%	15.5%	33.6%	19.8%	19.0%
HOSPITAL OUTPATIENT																
Emergency Room	3.5%	7.0%	10.7%	-24.1%	26.3%	-4.1%	1.9%	11.2%	13.3%	1.2%	8.7%	10.0%	4.6%	3.6%	13.4%	5.0%
Medical / Surgical	18.5%	-0.6%	17.8%	-12.5%	32.5%	15.9%	13.0%	18.0%	33.3%	16.6%	2.2%	19.1%	17.1%	13.2%	23.0%	16.8%
Other Services	2.4%	10.4%	13.1%	-22.5%	12.8%	-12.6%	10.4%	-5.1%	4.7%	1.4%	6.7%	8.1%	12.9%	10.8%	14.8%	12.6%
Psychiatric / Substance Abuse	21.6%	-27.2%	-11.4%	-18.9%	99.5%	61.7%	13.2%	9.1%	23.5%	17.8%	-22.9%	-9.2%	0.5%	0.2%	0.2%	0.4%
TOTAL	10.6%	4.1%	15.2%	-17.9%	24.5%	2.2%	9.3%	9.5%	19.7%	8.9%	4.4%	13.7%	35.0%	27.7%	51.4%	34.9%
PHYSICIAN SERVICES																
Anesthesia	-23.7%	28.7%	-1.9%	-26.0%	49.2%	10.4%	-4.6%	21.3%	15.7%	-23.8%	33.1%	1.4%	1.8%	2.1%	1.5%	1.8%
Chemotherapy / Radiation	-0.7%	-14.0%	-14.5%	-5.3%	7.9%	2.1%	-1.7%	9.1%	7.2%	-0.9%	-9.8%	-10.6%	0.3%	0.2%	0.3%	0.3%
Emergency Room	5.1%	2.7%	7.9%	-26.8%	36.1%	-0.3%	2.4%	-14.0%	-12.0%	1.6%	3.4%	5.0%	0.8%	0.6%	1.0%	0.8%
Immunizations / Injections / Allergy	-10.1%	5.7%	-5.0%	-22.0%	18.8%	-7.3%	-0.9%	-3.0%	-3.8%	-10.7%	6.3%	-5.0%	1.3%	0.4%	0.8%	1.1%
Inpatient Surgery	-2.2%	2.0%	-0.2%	0.0%	3.4%	3.4%	-10.4%	12.0%	0.3%	-2.1%	3.0%	0.8%	0.7%	1.3%	0.4%	0.8%
Inpatient Visits	-3.4%	-2.3%	-5.6%	17.3%	-2.8%	14.0%	-9.5%	-2.2%	-11.5%	0.3%	-1.0%	-0.7%	1.0%	1.4%	0.6%	1.0%
Lab & Pathology	-12.3%	17.9%	3.4%	0.6%	9.6%	10.3%	-3.0%	5.1%	2.0%	-7.8%	15.4%	6.4%	1.3%	5.9%	0.7%	2.0%
Maternity	0.2%	-4.5%	-4.2%	12.6%	1.2%	13.9%	17.6%	-11.5%	4.0%	4.4%	-5.1%	-0.9%	1.2%	1.2%	0.5%	1.1%
Office Visits	0.3%	2.6%	2.9%	-0.9%	8.2%	7.2%	-2.6%	5.4%	2.7%	0.1%	3.1%	3.1%	12.6%	3.9%	5.7%	10.6%
Other Services	-3.0%	8.2%	4.9%	-26.2%	22.7%	-9.5%	-6.2%	5.3%	-1.3%	-6.5%	9.3%	2.2%	15.0%	15.1%	10.5%	14.7%
Outpatient Surgery	7.6%	-2.2%	5.2%	7.1%	-3.4%	3.5%	24.5%	-10.3%	11.7%	8.4%	-2.9%	5.2%	3.6%	2.2%	2.6%	3.3%
Psychiatric / Substance Abuse	10.6%	3.2%	14.1%	-7.7%	11.5%	2.9%	8.5%	1.3%	10.0%	9.1%	4.2%	13.6%	4.1%	1.2%	0.7%	3.3%
Radiology	-0.7%	0.0%	-0.8%	-0.3%	9.0%	8.7%	1.0%	0.9%	1.9%	-0.6%	1.6%	1.0%	1.7%	1.3%	1.9%	1.6%
Therapies	6.4%	-0.3%	6.0%	14.5%	7.4%	23.0%	-0.6%	2.8%	2.2%	6.3%	-0.1%	6.2%	2.9%	0.3%	0.9%	2.3%
TOTAL	-0.6%	4.9%	4.3%	-11.5%	15.8%	2.5%	-0.6%	2.9%	2.3%	-2.0%	6.0%	3.9%	48.2%	37.0%	28.3%	44.8%
OTHER																
Ambulance	4.8%	0.4%	5.3%	16.1%	-34.9%	-24.4%	-1.4%	-13.2%	-14.4%	6.3%	-7.1%	-1.2%	0.7%	0.8%	0.3%	0.7%
Appliances (DME)	-9.5%	27.7%	15.6%	6.9%	-18.7%	-13.1%	-11.3%	0.1%	-11.2%	-6.6%	16.8%	9.1%	0.6%	0.9%	0.2%	0.6%
TOTAL	-1.8%	13.1%	11.1%	11.4%	-26.6%	-18.3%	-5.1%	-8.3%	-12.9%	0.2%	4.3%	4.4%	1.2%	1.7%	0.5%	1.3%
GRAND TOTAL	4.1%	11.8%	16.4%	-10.3%	15.2%	3.3%	4.8%	6.7%	11.8%	2.7%	9.5%	12.4%	100.0%	100.0%	100.0%	100.0%

West Virginia PEIA Non-Medicare Medical Total
Study Period of July 2020 to June 2024
(Allowed Claims)

48 Month Trends Summary - Excludes Drugs

	In-State			OOS NBC			OOS BC			Total			In-State	OOS NBC	OOS BC	Total
	Utilization	Cost / Service	Total Trend	Utilization	Cost / Service	Total Trend	Utilization	Cost / Service	Total Trend	Utilization	Cost / Service	Total Trend	Weight	Weight	Weight	Weight
HOSPITAL INPATIENT																
Maternity	0.6%	42.1%	42.9%	-16.8%	33.4%	11.0%	8.8%	8.5%	18.0%	-0.3%	31.9%	31.5%	1.6%	2.1%	2.3%	1.7%
Medical / Surgical	-0.5%	41.7%	41.1%	-3.4%	3.2%	-0.3%	-4.3%	5.1%	0.5%	-1.1%	22.5%	21.2%	12.5%	31.4%	18.4%	16.4%
Psychiatric / Substance Abuse	31.1%	18.9%	55.9%	10.5%	21.7%	34.5%	3.3%	9.0%	12.6%	23.4%	22.1%	50.6%	0.7%	0.6%	0.3%	0.7%
TOTAL	1.1%	40.7%	42.3%	-4.0%	5.4%	1.2%	-2.8%	5.5%	2.5%	-0.2%	23.4%	23.1%	14.8%	34.1%	21.0%	18.8%
HOSPITAL OUTPATIENT																
Emergency Room	5.2%	6.1%	11.7%	-15.5%	24.6%	5.3%	7.9%	7.1%	15.6%	3.6%	7.8%	11.7%	4.5%	3.5%	12.8%	5.0%
Medical / Surgical	14.6%	0.5%	15.3%	-6.0%	29.2%	21.4%	10.0%	7.0%	17.7%	13.3%	2.4%	16.1%	17.0%	12.2%	22.6%	16.6%
Other Services	1.6%	7.9%	9.6%	-13.8%	14.5%	-1.3%	8.0%	-1.8%	6.1%	0.9%	6.3%	7.3%	13.1%	10.5%	14.8%	12.8%
Psychiatric / Substance Abuse	22.5%	-10.2%	10.0%	-6.4%	59.2%	49.1%	14.8%	14.6%	31.6%	19.8%	-8.1%	10.1%	0.5%	0.2%	0.2%	0.4%
TOTAL	8.7%	3.9%	12.9%	-10.4%	22.9%	10.2%	8.9%	4.5%	13.8%	7.4%	4.5%	12.3%	35.2%	26.3%	50.3%	34.7%
PHYSICIAN SERVICES																
Anesthesia	-15.3%	16.8%	-1.0%	-13.5%	24.4%	7.6%	-0.6%	14.4%	13.7%	-14.9%	19.2%	1.4%	1.9%	2.0%	1.4%	1.9%
Chemotherapy / Radiation	3.9%	-9.5%	-5.9%	-4.0%	4.6%	0.5%	3.5%	-0.4%	3.1%	3.5%	-7.6%	-4.4%	0.3%	0.2%	0.3%	0.3%
Emergency Room	6.9%	1.7%	8.7%	-22.3%	31.4%	2.0%	12.1%	-19.3%	-9.6%	4.1%	1.7%	5.8%	0.8%	0.6%	1.1%	0.8%
Immunizations / Injections / Allergy	-6.8%	3.5%	-3.5%	-15.3%	15.5%	-2.2%	0.7%	-1.6%	-0.9%	-7.1%	4.1%	-3.2%	1.4%	0.4%	0.8%	1.2%
Inpatient Surgery	-3.5%	0.1%	-3.4%	-5.1%	3.7%	-1.6%	-6.2%	11.7%	4.8%	-3.9%	0.8%	-3.1%	0.8%	1.4%	0.4%	0.9%
Inpatient Visits	0.1%	-2.6%	-2.5%	11.3%	1.0%	12.5%	-9.7%	5.5%	-4.7%	1.7%	-0.9%	0.8%	1.0%	1.4%	0.7%	1.1%
Lab & Pathology	-2.7%	15.3%	12.2%	3.2%	5.9%	9.3%	2.8%	-0.1%	2.7%	-0.6%	11.2%	10.5%	1.2%	5.7%	0.7%	2.0%
Maternity	2.1%	-1.2%	0.9%	9.9%	-12.0%	-3.3%	7.8%	-4.5%	3.0%	4.6%	-4.3%	0.1%	1.2%	1.3%	0.5%	1.2%
Office Visits	3.5%	3.9%	7.5%	1.8%	7.7%	9.7%	0.6%	5.1%	5.8%	3.3%	4.2%	7.6%	12.6%	3.7%	5.6%	10.5%
Other Services	-2.4%	10.6%	8.0%	-23.4%	16.0%	-11.2%	-2.5%	6.7%	4.0%	-5.3%	9.7%	3.9%	14.9%	16.5%	10.4%	14.9%
Outpatient Surgery	9.5%	-6.7%	2.3%	6.8%	-0.6%	6.2%	25.4%	-18.3%	2.5%	10.1%	-6.7%	2.7%	3.7%	2.1%	2.7%	3.4%
Psychiatric / Substance Abuse	9.5%	5.0%	14.9%	-10.6%	18.3%	5.8%	10.8%	5.0%	16.3%	7.7%	6.4%	14.6%	4.0%	1.1%	0.7%	3.3%
Radiology	2.2%	-1.3%	0.8%	0.3%	10.5%	10.9%	2.1%	0.3%	2.4%	2.0%	0.4%	2.4%	1.7%	1.3%	2.0%	1.7%
Therapies	4.2%	0.9%	5.2%	4.7%	8.3%	13.3%	0.3%	4.5%	4.8%	4.0%	1.2%	5.3%	3.0%	0.3%	0.9%	2.4%
TOTAL	1.3%	5.2%	6.5%	-10.1%	11.2%	0.0%	2.5%	2.2%	4.7%	-0.1%	5.5%	5.4%	48.8%	37.8%	28.2%	45.2%
OTHER																
Ambulance	5.2%	0.4%	5.7%	15.7%	-22.9%	-10.8%	2.9%	-11.2%	-8.7%	6.6%	-5.0%	1.3%	0.7%	0.8%	0.3%	0.7%
Appliances (DME)	-3.8%	14.3%	10.1%	11.5%	-21.3%	-12.3%	6.2%	-1.4%	4.7%	-0.9%	4.3%	3.4%	0.6%	0.9%	0.2%	0.6%
TOTAL	1.0%	7.0%	8.1%	13.5%	-22.0%	-11.5%	4.0%	-7.8%	-4.1%	3.0%	-0.5%	2.5%	1.3%	1.8%	0.5%	1.3%
GRAND TOTAL	3.8%	10.0%	14.2%	-7.7%	11.7%	3.1%	4.6%	4.0%	8.8%	2.6%	8.4%	11.2%	100.0%	100.0%	100.0%	100.0%

West Virginia PEIA Non-Medicare Medical Total
Study Period of July 2023 to June 2024
(Allowed Claims)

12 Month Summary - Excludes Drugs

	Number of Visits							Total Allowed Cost						
	<u>In-State</u>	<u>OOS NBC</u>	<u>OOS BC</u>	<u>Total</u>	<u>In-State %</u>	<u>OOS NBC %</u>	<u>OOS BC %</u>	<u>In-State</u>	<u>OOS NBC</u>	<u>OOS BC</u>	<u>Total</u>	<u>In-State %</u>	<u>OOS NBC %</u>	<u>OOS BC %</u>
HOSPITAL INPATIENT														
Maternity	4,377	291	373	5,041	86.8%	5.8%	7.4%	15,423,407	3,856,261	1,697,352	20,977,020	73.5%	18.4%	8.1%
Medical / Surgical	8,011	1,354	461	9,826	81.5%	13.8%	4.7%	121,245,527	44,745,119	8,651,090	174,641,735	69.4%	25.6%	5.0%
Psychiatric / Substance Abuse	1,219	305	34	1,558	78.2%	19.6%	2.2%	7,689,218	1,245,208	198,444	9,132,870	84.2%	13.6%	2.2%
TOTAL	13,608	1,950	868	16,426	82.8%	11.9%	5.3%	144,358,151	49,846,589	10,546,886	204,751,626	70.5%	24.3%	5.2%
HOSPITAL OUTPATIENT														
Emergency Room	35,275	2,237	2,979	40,491	87.1%	5.5%	7.4%	28,028,006	4,640,008	8,129,433	40,797,448	68.7%	11.4%	19.9%
Medical / Surgical	207,103	7,692	5,537	220,333	94.0%	3.5%	2.5%	108,550,544	19,669,454	16,268,055	144,488,052	75.1%	13.6%	11.3%
Other Services	264,584	10,091	8,921	283,596	93.3%	3.6%	3.1%	82,591,742	12,958,728	8,091,349	103,641,820	79.7%	12.5%	7.8%
Psychiatric / Substance Abuse	10,337	431	207	10,975	94.2%	3.9%	1.9%	1,881,312	289,814	130,433	2,301,559	81.7%	12.6%	5.7%
TOTAL	517,299	20,451	17,645	555,395	93.1%	3.7%	3.2%	221,051,604	37,558,004	32,619,270	291,228,879	75.9%	12.9%	11.2%
PHYSICIAN SERVICES														
Anesthesia	44,781	6,619	2,414	53,815	83.2%	12.3%	4.5%	9,741,646	3,056,382	920,491	13,718,519	71.0%	22.3%	6.7%
Chemotherapy / Radiation	29,733	1,714	1,564	33,011	90.1%	5.2%	4.7%	1,366,664	354,009	176,524	1,897,198	72.0%	18.7%	9.3%
Emergency Room	37,251	2,337	2,411	41,999	88.7%	5.6%	5.7%	4,654,299	748,521	530,673	5,933,493	78.4%	12.6%	8.9%
Immunizations / Injections / Allergy	84,753	5,485	3,606	93,844	90.3%	5.8%	3.8%	7,264,909	514,179	422,325	8,201,413	88.6%	6.3%	5.1%
Inpatient Surgery	5,958	1,311	271	7,540	79.0%	17.4%	3.6%	3,869,265	1,678,914	198,369	5,746,548	67.3%	29.2%	3.5%
Inpatient Visits	29,323	10,253	1,247	40,822	71.8%	25.1%	3.1%	5,231,843	2,367,514	331,924	7,931,282	66.0%	29.9%	4.2%
Lab & Pathology	187,536	112,595	13,615	313,745	59.8%	35.9%	4.3%	7,554,036	8,376,374	417,806	16,348,216	46.2%	51.2%	2.6%
Maternity	27,796	17,332	1,768	46,896	59.3%	37.0%	3.8%	6,147,921	1,782,522	286,123	8,216,566	74.8%	21.7%	3.5%
Office Visits	740,060	42,076	29,311	811,447	91.2%	5.2%	3.6%	71,391,639	5,378,135	3,124,674	79,894,447	89.4%	6.7%	3.9%
Other Services	389,508	42,705	16,966	449,180	86.7%	9.5%	3.8%	88,449,410	17,936,208	5,814,792	112,200,410	78.8%	16.0%	5.2%
Outpatient Surgery	166,854	11,624	11,796	190,274	87.7%	6.1%	6.2%	20,434,831	2,906,343	1,501,700	24,842,874	82.3%	11.7%	6.0%
Psychiatric / Substance Abuse	215,715	15,855	4,863	236,433	91.2%	6.7%	2.1%	25,731,054	1,527,962	441,335	27,700,351	92.9%	5.5%	1.6%
Radiology	192,718	21,804	7,876	222,398	86.7%	9.8%	3.5%	9,103,865	1,906,924	1,062,572	12,073,361	75.4%	15.8%	8.8%
Therapies	191,823	6,313	7,438	205,574	93.3%	3.1%	3.6%	16,888,187	426,486	499,447	17,814,120	94.8%	2.4%	2.8%
TOTAL	2,343,809	298,023	105,147	2,746,978	85.3%	10.8%	3.8%	277,829,570	48,960,473	15,728,755	342,518,798	81.1%	14.3%	4.6%
OTHER														
Ambulance	7,551	1,563	308	9,422	80.1%	16.6%	3.3%	3,933,191	853,419	139,609	4,926,218	79.8%	17.3%	2.8%
Appliances (DME)	21,155	5,647	1,025	27,828	76.0%	20.3%	3.7%	3,773,928	1,060,415	100,087	4,934,430	76.5%	21.5%	2.0%
TOTAL	28,707	7,210	1,334	37,250	77.1%	19.4%	3.6%	7,707,119	1,913,834	239,695	9,860,649	78.2%	19.4%	2.4%
GRAND TOTAL	2,903,422	327,634	124,993	3,356,049	86.5%	9.8%	3.7%	650,946,444	138,278,900	59,134,607	848,359,951	76.7%	16.3%	7.0%

West Virginia PEIA Non-Medicare Prescription Drugs Total

Study Period of July 2020 to June 2024

(Allowed Claims)

24-Month Trends Summary

	<u>Utilization</u>	<u>Cost / Prescription</u>	<u>Total Trend</u>
Non-Medicare	5.0%	41.2%	48.2%

36-Month Trends Summary

	<u>Utilization</u>	<u>Cost / Prescription</u>	<u>Total Trend</u>
Non-Medicare	3.4%	8.5%	12.2%

48-Month Trends Summary

	<u>Utilization</u>	<u>Cost / Prescription</u>	<u>Total Trend</u>
Non-Medicare	3.0%	7.5%	10.8%

Appendix A


NON-MEDICARE CLAIMS **Excluding Drugs**

GRAND TOTAL


24-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
7.5%	11.6%	20.0%

36-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
2.7%	9.5%	12.4%


48-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
2.6%	8.4%	11.2%



Total Claims - Excluding Drugs



Total Claims - Excluding Drugs



NON-MEDICARE CLAIMS
Excluding Drugs


HOSPITAL INPATIENT

TOTAL


24-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
7.3%	45.8%	56.5%

36-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
2.5%	27.1%	30.2%


48-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
-0.2%	23.4%	23.1%



Total Hospital Inpatient Claims - Excluding Drugs



Total Hospital Inpatient Claims - Excluding Drugs



NON-MEDICARE CLAIMS
Excluding Drugs


HOSPITAL OUTPATIENT

TOTAL


24-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
18.1%	1.5%	19.8%

36-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
8.9%	4.4%	13.7%


48-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
7.4%	4.5%	12.3%



Total Hospital Outpatient Claims - Excluding Drugs



Total Hospital Outpatient Claims - Excluding Drugs



NON-MEDICARE CLAIMS
Excluding Drugs


PHYSICIAN SERVICES

TOTAL


24-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
-0.4%	4.2%	3.8%

36-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
-2.0%	6.0%	3.9%


48-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
-0.1%	5.5%	5.4%



Total Physician Services Claims - Excluding Drugs



Total Physician Services Claims - Excluding Drugs



NON-MEDICARE CLAIMS
Excluding Drugs


OTHER

TOTAL


24-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
-6.5%	12.4%	5.1%

36-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
0.2%	4.3%	4.4%


48-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
3.0%	-0.5%	2.5%



Total Other Claims - Excluding Drugs



Total Other Claims - Excluding Drugs



NON-MEDICARE CLAIMS
Excluding Drugs

HOSPITAL INPATIENT


Maternity

24-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
0.9%	62.8%	64.4%


36-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
-1.1%	35.3%	33.8%

48-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
-0.3%	31.9%	31.5%


Hospital Inpatient - Maternity



Hospital Inpatient - Maternity



Hospital Inpatient - Maternity



NON-MEDICARE CLAIMS
Excluding Drugs

HOSPITAL INPATIENT


Medical / Surgical

24-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
5.0%	44.8%	52.0%


36-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
1.1%	26.4%	27.8%

48-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
-1.1%	22.5%	21.2%


Hospital Inpatient - Medical / Surgical



Hospital Inpatient - Medical / Surgical



Hospital Inpatient - Medical / Surgical



NON-MEDICARE CLAIMS
Excluding Drugs

HOSPITAL INPATIENT


Psychiatric / Substance Abuse

24-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
72.8%	28.9%	122.8%


36-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
44.3%	21.3%	75.0%

48-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
23.4%	22.1%	50.6%


Hospital Inpatient - Psychiatric / Substance Abuse



Hospital Inpatient - Psychiatric / Substance Abuse



Hospital Inpatient - Psychiatric / Substance Abuse



NON-MEDICARE CLAIMS
Excluding Drugs

HOSPITAL OUTPATIENT


Emergency Room

24-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
2.0%	6.5%	8.7%


36-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
1.2%	8.7%	10.0%

48-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
3.6%	7.8%	11.7%


Hospital Outpatient - Emergency Room



Hospital Outpatient - Emergency Room



Hospital Outpatient - Emergency Room



NON-MEDICARE CLAIMS
Excluding Drugs

HOSPITAL OUTPATIENT


Medical / Surgical

24-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
27.5%	-2.1%	24.9%


36-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
16.6%	2.2%	19.1%

48-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
13.3%	2.4%	16.1%


Hospital Outpatient - Medical / Surgical



Hospital Outpatient - Medical / Surgical



Hospital Outpatient - Medical / Surgical



**NON-MEDICARE CLAIMS
Excluding Drugs**

HOSPITAL OUTPATIENT


Other Services

24-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
11.4%	5.6%	17.7%


36-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
1.4%	6.7%	8.1%

48-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
0.9%	6.3%	7.3%


Hospital Outpatient - Other Services



Hospital Outpatient - Other Services



Hospital Outpatient - Other Services



NON-MEDICARE CLAIMS
Excluding Drugs

HOSPITAL OUTPATIENT


Psychiatric / Substance Abuse

24-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
21.3%	-38.7%	-25.7%


36-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
17.8%	-22.9%	-9.2%

48-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
19.8%	-8.1%	10.1%


Hospital Outpatient - Psychiatric / Substance Abuse



Hospital Outpatient - Psychiatric / Substance Abuse



Hospital Outpatient - Psychiatric / Substance Abuse



NON-MEDICARE CLAIMS
Excluding Drugs

PHYSICIAN SERVICES


Anesthesia

24-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
-18.0%	26.8%	3.9%


36-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
-23.8%	33.1%	1.4%

48-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
-14.9%	19.2%	1.4%


Physician Services - Anesthesia



Physician Services - Anesthesia



Physician Services - Anesthesia



NON-MEDICARE CLAIMS
Excluding Drugs

PHYSICIAN SERVICES


Chemotherapy / Radiation

24-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
-4.8%	0.7%	-4.1%


36-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
-0.9%	-9.8%	-10.6%

48-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
3.5%	-7.6%	-4.4%


Physician Services - Chemotherapy Radiation



Physician Services - Chemotherapy Radiation



Physician Services - Chemotherapy Radiation



NON-MEDICARE CLAIMS
Excluding Drugs

PHYSICIAN SERVICES


Emergency Room

24-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
-2.0%	7.8%	5.7%


36-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
1.6%	3.4%	5.0%

48-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
4.1%	1.7%	5.8%


Physician Services - Emergency Room



Physician Services - Emergency Room



Physician Services - Emergency Room



NON-MEDICARE CLAIMS
Excluding Drugs

PHYSICIAN SERVICES


Immunizations / Injections / Allergy

24-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
-21.3%	9.9%	-13.5%


36-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
-10.7%	6.3%	-5.0%

48-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
-7.1%	4.1%	-3.2%


Physician Services - Immunizations / Allergy



Physician Services - Immunizations / Allergy



Physician Services - Immunizations / Allergy



NON-MEDICARE CLAIMS
Excluding Drugs

PHYSICIAN SERVICES


Inpatient Surgery

24-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
-1.9%	-4.0%	-5.8%


36-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
-2.1%	3.0%	0.8%

48-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
-3.9%	0.8%	-3.1%


Physician Services - Inpatient Surgery



Physician Services - Inpatient Surgery



Physician Services - Inpatient Surgery



NON-MEDICARE CLAIMS
Excluding Drugs


PHYSICIAN SERVICES

Inpatient Visits


24-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
4.1%	4.6%	8.8%

36-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
0.3%	-1.0%	-0.7%


48-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
1.7%	-0.9%	0.8%



Physician Services - Inpatient Visits



Physician Services - Inpatient Visits



NON-MEDICARE CLAIMS
Excluding Drugs

PHYSICIAN SERVICES


Lab & Pathology

24-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
-3.7%	13.8%	9.7%


36-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
-7.8%	15.4%	6.4%

48-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
-0.6%	11.2%	10.5%


Physician Services - Lab & Pathology



Physician Services - Lab & Pathology



Physician Services - Lab & Pathology



NON-MEDICARE CLAIMS
Excluding Drugs


PHYSICIAN SERVICES

Maternity


24-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
6.1%	-8.1%	-2.5%

36-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
4.4%	-5.1%	-0.9%


48-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
4.6%	-4.3%	0.1%



Physician Services - Maternity



Physician Services - Maternity



NON-MEDICARE CLAIMS
Excluding Drugs


PHYSICIAN SERVICES

Office Visits


24-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
2.8%	-0.1%	2.7%

36-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
0.1%	3.1%	3.1%


48-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
3.3%	4.2%	7.6%



Physician Services - Office Visits



Physician Services - Office Visits



NON-MEDICARE CLAIMS
Excluding Drugs


PHYSICIAN SERVICES

Other Services


24-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
-4.1%	6.3%	2.0%

36-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
-6.5%	9.3%	2.2%


48-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
-5.3%	9.7%	3.9%



Physician Services - Other Services



Physician Services - Other Services



NON-MEDICARE CLAIMS
Excluding Drugs

PHYSICIAN SERVICES


Outpatient Surgery

24-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
5.3%	1.6%	6.9%


36-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
8.4%	-2.9%	5.2%

48-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
10.1%	-6.7%	2.7%


Physician Services - Outpatient Surgery



Physician Services - Outpatient Surgery



Physician Services - Outpatient Surgery



NON-MEDICARE CLAIMS
Excluding Drugs

PHYSICIAN SERVICES


Psychiatric / Substance Abuse

24-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
9.9%	4.6%	15.0%


36-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
9.1%	4.2%	13.6%

48-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
7.7%	6.4%	14.6%


Physician Services - Psychiatric / Substance Abuse



Physician Services - Psychiatric / Substance Abuse



Physician Services - Psychiatric / Substance Abuse



NON-MEDICARE CLAIMS
Excluding Drugs


PHYSICIAN SERVICES

Radiology


24-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
1.3%	-2.5%	-1.2%

36-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
-0.6%	1.6%	1.0%


48-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
2.0%	0.4%	2.4%



Physician Services - Radiology



Physician Services - Radiology



NON-MEDICARE CLAIMS
Excluding Drugs


PHYSICIAN SERVICES

Therapies


24-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
7.5%	-3.5%	3.7%

36-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
6.3%	-0.1%	6.2%


48-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
4.0%	1.2%	5.3%



Physician Services - Therapies



Physician Services - Therapies



NON-MEDICARE CLAIMS Excluding Drugs

OTHER


Ambulance

24-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
-5.8%	0.2%	-5.6%


36-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
6.3%	-7.1%	-1.2%

48-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
6.6%	-5.0%	1.3%


Other - Ambulance



Other - Ambulance



Other - Ambulance



NON-MEDICARE CLAIMS
Excluding Drugs

OTHER


Appliances (DME)

24-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
-7.2%	25.7%	16.6%


36-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
-6.6%	16.8%	9.1%

48-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Service</u>	<u>Total Trend</u>
-0.9%	4.3%	3.4%


Other - Appliances (DME)



Other - Appliances (DME)



Other - Appliances (DME)




Appendix B

NON-MEDICARE PRESCRIPTION DRUGS


24-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Prescription</u>	<u>Total Trend</u>
5.0%	41.2%	48.2%

36-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Prescription</u>	<u>Total Trend</u>
3.4%	8.5%	12.2%


48-Month Trends Summary		
<u>Utilization</u>	<u>Cost / Prescription</u>	<u>Total Trend</u>
3.0%	7.5%	10.8%



Non-Medicare Prescription Drugs



Non-Medicare Prescription Drugs



Appendix C – Prescription Drug Trends

Continuing Care Actuaries analyzed prescription drug experience provided by CVS in aggregate, by major indicator and in particular, specialty drugs. We analyzed the prescription drug trends using a 24, 36, and 48 month actuarial basis. We found the 24-month basis as the methodology that is most likely to produce accurate future trends. Under this methodology, utilization had a 0.4% trend and unit cost had a 16.9% trend, resulting in a composite trend of 14.4% on an unadjusted basis. The chart below summarizes components of the unadjusted prescription drug trend for the past ten years.

Year	Utilization	Unit Cost	Composite Trend
2013	0.0%	-5.8%	-5.5%
2014	-1.5%	6.2%	4.5%
2015	3.9%	7.9%	11.5%
2016	-0.7%	8.7%	6.9%
2017	-2.4%	12.2%	7.1%
2018	-29.0%	44.0%	2.3%
2019	-1.1%	13.4%	10.3%
2020	2.2%	7.8%	8.4%
2021	0.3%	14.2%	12.7%
2022	5.1%	10.1%	14.8%
2023	4.0%	1.4%	3.9%
2024	0.4%	16.9%	14.4%

Prior to this analysis, the financial plan was developed using a 15.0% trend for fiscal year 2025. Based on results and future expectations, Continuing Care Actuaries has chosen to use a gross drug trend assumption of 15.0% and drug rebate trend of 5.0% for fiscal year 2025 in the financial plan.

Brand Patent Expirations

This drug trend assumption has been made in consideration of recent drug experience, as well as future blockbuster drugs that are expected to lose their patent in the upcoming years. Overall, we can expect fewer expirations than PEIA has experienced in the past. These drugs include:

Drug	Patent Expiration	2023 Ingredient Cost		2024 Ingredient Cost	
		Amount	%	Amount	%
Eliquis	2028	\$3,191,480	0.79%	\$4,282,218	0.92%
Trulicity	2027	14,906,653	3.69%	9,670,268	2.09%
Ibrance	2027	2,270,089	0.56%	1,515,397	0.33%
Revlimid	2026	3,239,015	0.80%	2,837,692	0.61%
Entresto	2025	2,371,527	0.59%	2,892,256	0.62%
Total		\$25,978,764	6.42%	\$21,197,831	4.58%

Specialty Drugs

Specialty drugs have continued to be a concern for PEIA due to the relatively rapid growth in utilization and unit cost. Nationally, specialty drug spend is approximately 52% [\[Pharmacy Times\]](#) of all drug spend. For PEIA, it is approximately 42% of all drug spend. The following chart shows the percent of plan drug expenditures in specialty drugs in the past few years. The days supply decreased by 6.95% in 2024, which is a better measure of utilization.

Period	Specialty Drugs				
	Total Specialty Cost (\$M)	Percent of Total Cost	Specialty Cost Growth	Number of Specialty Rx	Specialty Rx Growth
FY 2013	\$34.0	18.00%	24.30%	11,167	5.50%
FY 2014	\$35.8	18.60%	5.30%	10,938	-2.10%
FY 2015	\$40.2	18.70%	12.40%	11,028	0.80%
FY 2016	\$48.5	21.10%	20.70%	11,128	0.90%
FY 2017	\$73.6	29.90%	51.50%	17,731	59.30%
FY 2018	\$78.3	31.30%	6.50%	16,153	-8.90%
FY 2019	\$88.8	31.98%	13.35%	17,354	7.44%
FY 2020	\$100.5	33.41%	13.21%	20,210	16.46%
FY 2021	\$118.7	35.00%	18.06%	21,863	8.18%
FY 2022	\$141.4	36.32%	19.11%	23,775	8.75%
FY 2023	\$169.9	42.02%	20.14%	21,922	-7.79%
FY 2024	\$194.31	41.97%	14.39%	23,131	5.51%

The following chart shows the top 10 brand name specialty drugs and their total cost in 2024:

2024 Rank	2024 Brand Name	2023 Cost	2024 Cost	Total Growth
1	HUMIRA(CF) PEN	26,292,343	27,689,012	5.31%
2	STELARA	12,564,255	15,450,862	22.97%
3	SKYRIZI PEN	5,761,522	9,265,149	60.81%
4	TREMFYA	6,230,043	7,563,887	21.41%
5	TALTZ AUTOINJECTOR	5,203,546	6,120,159	17.62%
6	OTEZLA	5,397,886	5,466,523	1.27%
7	TRIKAFTA	4,153,749	5,295,448	27.49%
8	DUPIXENT PEN	3,984,556	5,273,378	32.35%
9	RINVOQ	2,621,675	5,064,404	93.17%
10	<u>ENBREL SURECLICK</u>	<u>4,970,276</u>	<u>4,790,719</u>	<u>-3.61%</u>
	Total	\$77,179,851	\$91,979,540	19.18%
	Percent of Specialty Cost	45.43%	47.34%	

Indicator Categories

Continuing Care Actuaries reviewed the individual prescription data items for Fiscal Years 2023 and 2024. A total of 2,008,040 scripts were written for approximately 2,111 different kinds of prescriptions in 2024. The prescriptions were grouped by indicator codes, providing a basis to develop the Fiscal Year 2024 trend by indicator code. The top 40 indicator codes were analyzed, which accounted for 85.9%, down from 90.4% in 2023.

Three of the top five indicators had material increases in cost. PEIA members spend the most on Incretin Mimetics. The following chart lists the top 5 and the total drug spend each year.

<u>Rank</u>	<u>Indicator</u>	<u>2023 Cost</u>	<u>Indicator</u>	<u>2024 Cost</u>
1	INCRETIN MIMETICS	\$64,769,436	INCRETIN MIMETICS	\$95,309,184
2	ANTINEOPLASTIC AGENTS	27,593,362	ANTINEOPLASTIC AGENTS	32,190,194
3	DISEASE-MODIFYING ANTIRHEUMATIC AGENTS	28,368,059	DISEASE-MODIFYING ANTIRHEUMATIC AGENTS	30,021,039
4	SODIUM-GLUC COTRANSPORT 2 SGLT2 INHIB	18,766,572	SODIUM-GLUC COTRANSPORT 2 SGLT2 INHIB	20,634,558
5	INSULINS	24,746,633	INSULINS	19,893,282

The charts on the next few pages summarize the utilization and cost per service for formulary and non-formulary drugs for each indicator code. The “Top Five Increases in Drug Trends” chart is calculated with indicators which grossed at least \$200,000 in ingredient cost in 2024.

On pages C-7 and C-8, we list the top 40 indicators and summarize the utilization and cost statistics. These top 40 indicators represent 85.9% of total program costs.

On page C-13, we list the top 20 drugs and summarize the formulary and non-formulary cost statistics. These top 20 drugs represent 47.0% of total program costs.

On pages C-16 to C-20 we show a detailed analysis concerning the top 5 indicators. These analyses include drugs with the highest total ingredient cost, the amount per script, and a breakout of how much was spent on generic, formulary, and non-formulary drugs.

Indicators with the Largest Dollar Increase

Indication	2023 Total Ingredient Cost	2024 Total Ingredient Cost	Total Increase
INCRETIN MIMETICS	\$64,769,436	\$95,309,184	\$30,539,748
IMMUNOMODULATORY AGENTS - 84:06	14,388,440	19,754,825	5,366,386
ANTINEOPLASTIC AGENTS	27,593,362	32,190,194	4,596,832
INTERLEUKIN-MEDIATED AGENTS	21,829,698	26,030,827	4,201,129
CALCITONIN GENE-RELATED PEPTIDE ANTAG	7,822,055	10,727,762	2,905,707

Indicators with the Largest Increase as a Percentage

Indication	2023 Total Ingredient Cost	2024 Total Ingredient Cost	Total Increase
CORONAVIRUS - COVID-19	\$58,440	\$1,031,398	1,664.9%
HCV ANTIVIRALS	509,682	1,436,979	181.9%
JANUS KINASE INHIBITORS - 84:06	206,945	521,224	151.9%
ANTIDIABETIC AGENTS MISCELLANEOUS	207,362	519,070	150.3%
CMV ANTIVIRALS	192,310	473,617	146.3%

Indicators with the Largest Increase in Claim Numbers

Indication	2023 Prescriptions	2024 Prescriptions	Utilization Increase
INCRETIN MIMETICS	40,835	61,548	20,713
RESPIRATORY AND CNS STIMULANTS	17,978	20,434	2,456
AMPHETAMINES	30,774	33,150	2,376
ANTICONVULSANTS MISCELLANEOUS	19,703	21,649	1,946
OPIOID PARTIAL AGONISTS	4,544	6,481	1,937

Indicators with the Largest Utilization Increase Percentage

Indication	2023 Prescriptions	2024 Prescriptions	Utilization Increase
HCV ANTIVIRALS	22	63	186.4%
CMV ANTIVIRALS	22	57	159.1%
JANUS KINASE INHIBITORS - 84:06	105	213	102.9%
INTERLEUKIN ANTAGONISTS	241	461	91.3%
IGG1 MONOCLONAL ANTIBODIES	84	136	61.9%

Indicators with the Largest Increase in Cost per Prescription

Indication	2023 Ingredient Cost Per Prescription	2024 Ingredient Cost Per Prescription	Ingredient Cost Per Prescription Increase
ANTIDIABETIC AGENTS MISCELLANEOUS	\$18,851	\$32,442	\$13,591
AMYOTROPHIC LATERAL SCLEROSIS - ALS AGEN	8,379	14,043	5,664
VASODILATING AGENTS RESPIRATORY TRACT	13,500	15,884	2,383
GI DRUGS MISCELLANEOUS	1,267	2,749	1,483
IMMUNOMODULATORY AGENTS - 84:06	8,657	9,712	1,055

Indicators with the Largest Percentage Increase in Cost per Prescription

Indication	2023 Ingredient Cost Per Prescription	2024 Ingredient Cost Per Prescription	Ingredient Cost Per Prescription Increase
CORONAVIRUS - COVID-19	12	292	2,346.2%
GI DRUGS MISCELLANEOUS	1,267	2,749	117.0%
DEVICES	123	242	97.1%
BASIC OINTMENTS AND PROTECTANTS	308	559	81.7%
ANTIDIABETIC AGENTS MISCELLANEOUS	18,851	32,442	72.1%

Drug Indicators by Highest Cost

<u>Rank</u>	<u>Indicator</u>	<u>Number of Prescriptions</u>	<u>Cost Per Prescription</u>	<u>Program Costs</u>	<u>Formulary Percent (cost)</u>	<u>Formulary Percent (Scripts)</u>
1	INCRETIN MIMETICS	61,548	\$1,548.53	\$95,309,184	99.77%	99.82%
2	ANTINEOPLASTIC AGENTS	9,059	3,553.39	32,190,194	97.56%	90.19%
3	DISEASE-MODIFYING ANTIRHEUMATIC AGENTS	3,869	7,759.38	30,021,039	100.00%	100.00%
4	INTERLEUKIN-MEDIATED AGENTS	2,182	11,929.80	26,030,827	82.40%	89.84%
5	SODIUM-GLUC COTRANSPORT 2 SGLT2 INHIB	14,057	1,467.92	20,634,558	99.42%	99.48%
6	INSULINS	16,403	1,212.78	19,893,282	99.27%	99.53%
7	IMMUNOMODULATORY AGENTS - 84:06	2,034	9,712.30	19,754,825	99.51%	99.49%
8	TUMOR NECROSIS FACTOR INHIBITORS	2,153	8,123.22	17,489,300	98.19%	98.73%
9	SKIN AND MUCOUS MEMBRANE AGENTS MISC	4,022	2,886.57	11,609,781	99.65%	99.96%
10	CALCITONIN GENE-RELATED PEPTIDE ANTAG	9,462	1,133.77	10,727,762	99.92%	99.92%
11	ANTICOAGULANTS	10,018	978.11	9,798,738	99.85%	99.93%
12	JANUS KINASE INHIBITORS - 90:24	1,291	6,091.15	7,863,678	94.66%	96.50%
13	DEVICES	32,355	242.32	7,840,158	98.87%	98.55%
14	DIPEPTIDYL PEPTIDASE-4 DPP-4 INHIBITORS	4,429	1,389.82	6,155,495	99.73%	99.78%
15	PHOSPHODIESTERASE-4 INHIBITORS - 90:24	1,202	4,547.86	5,466,523	100.00%	100.00%
16	ANTIPSYCHOTIC AGENTS	15,607	341.50	5,329,801	86.77%	14.53%
17	CYSTIC FIBROSIS CFTR CORRECTORS	203	26,085.95	5,295,448	100.00%	100.00%
18	ANTIDEPRESSANTS	165,508	31.89	5,277,903	99.75%	91.67%
19	WAKEFULNESS-PROMOTING AGENTS	2,386	1,913.39	4,565,341	96.81%	78.40%
20	ADRENALS	75,398	57.44	4,330,665	99.72%	96.29%

Drug Indicators by Highest Cost (continued)

<u>Rank</u>	<u>Indicator</u>	<u>Number of Prescriptions</u>	<u>Cost Per Prescription</u>	<u>Program Costs</u>	<u>Formulary Percent (cost)</u>	<u>Formulary Percent (Scripts)</u>
21	GUANYLATE CYCLASE C - GCC RECEPT AGONIST	3,370	\$1,185.38	\$3,994,744	100.00%	100.00%
22	ANTIRETROVIRALS	1,828	1,940.06	3,546,430	99.12%	98.49%
23	VASODILATING AGENTS RESPIRATORY TRACT	220	15,883.50	3,494,370	86.36%	76.39%
24	ANTICHOLINERGIC AGENTS RESPIR TRACT	2,474	1,301.83	3,220,728	100.00%	100.00%
25	ANTI-INFLAMMATORY AGENTS EENT	1,780	1,694.35	3,015,943	95.06%	96.74%
26	ANGIOTENSIN II RECEPT ANTAGONIST/NEPROLYS	1,840	1,571.88	2,892,256	100.00%	100.00%
27	AMPHETAMINES	33,150	85.48	2,833,575	95.76%	81.90%
28	HEMATOPOIETIC AGENTS	297	8,982.84	2,667,903	100.00%	100.00%
29	FUMARATES	331	7,690.62	2,545,596	96.68%	96.12%
30	PITUITARY	757	3,092.85	2,341,290	95.51%	95.10%
31	CONTRACEPTIVES	35,948	64.77	2,328,203	99.18%	93.23%
32	ANTIBACTERIALS MISCELLANEOUS	15,977	140.98	2,252,381	99.96%	99.97%
33	INTERLEUKIN ANTAGONISTS	461	4,783.22	2,205,062	97.83%	89.35%
34	MONOCLONAL ANTIBODIES - 90:04	261	8,386.94	2,188,991	100.00%	100.00%
35	DIGESTANTS	684	3,103.09	2,122,513	100.00%	100.00%
36	HMG-COA REDUCTASE INHIBITORS	86,726	24.05	2,085,456	99.98%	99.66%
37	PROTON-PUMP INHIBITORS	70,416	29.32	2,064,558	99.96%	99.34%
38	ANTICONVULSANTS MISCELLANEOUS	21,649	94.42	2,044,101	98.63%	62.97%
39	ANTIMUSCARINICS/ANTISPASMODICS	8,692	234.11	2,034,860	99.39%	98.84%
40	THYROID AGENTS	49,669	40.76	2,024,276	88.31%	67.60%
	<u>All Other Indicators</u>	1,238,324	52.89	65,500,229	99.43%	82.91%
	Total	2,008,040	230.57	462,987,968	99.03%	93.99%

Drug Indicators by Highest Cost
Analysis of Formulary Distribution

<u>Rank</u>	<u>Indicator</u>	Formulary			Non-Formulary		
		<u>Number of Scripts</u>	<u>Ingredient Costs</u>	<u>Cost Per Script</u>	<u>Number of Scripts</u>	<u>Ingredient Costs</u>	<u>Cost Per Script</u>
1	INCRETIN MIMETICS	61,406	\$95,133,442	\$1,549.25	142	\$175,742	\$1,237.62
2	ANTINEOPLASTIC AGENTS	8,838	29,033,071	3,285.03	221	3,157,123	14,285.62
3	DISEASE-MODIFYING ANTIRHEUMATIC AGENTS	3,869	30,021,039	7,759.38	-	-	-
4	INTERLEUKIN-MEDIATED AGENTS	1,798	23,385,244	13,006.25	384	2,645,582	6,889.54
5	SODIUM-GLUC COTRANSPORT 2 SGLT2 INHIB	13,975	20,527,315	1,468.86	82	107,243	1,307.85
6	INSULINS	16,283	19,799,875	1,215.98	120	93,407	778.39
7	IMMUNOMODULATORY AGENTS - 84:06	2,024	19,654,940	9,710.94	10	99,886	9,988.59
8	TUMOR NECROSIS FACTOR INHIBITORS	2,114	17,267,083	8,167.97	39	222,217	5,697.88
9	SKIN AND MUCOUS MEMBRANE AGENTS MISC	4,008	11,605,507	2,895.59	14	4,274	305.26
10	CALCITONIN GENE-RELATED PEPTIDE ANTAG	9,454	10,719,366	1,133.84	8	8,396	1,049.49
11	ANTICOAGULANTS	10,003	9,792,200	978.93	15	6,537	435.83
12	JANUS KINASE INHIBITORS - 90:24	1,222	7,588,467	6,209.87	69	275,211	3,988.57
13	DEVICES	31,991	7,726,803	241.53	364	113,355	311.42
14	DIPEPTIDYL PEPTIDASE-4 DPP-4 INHIBITORS	4,417	6,141,737	1,390.48	12	13,757	1,146.44
15	PHOSPHODIESTERASE-4 INHIBITORS - 90:24	1,202	5,466,523	4,547.86	-	-	-
16	ANTIPSYCHOTIC AGENTS	13,542	774,288	57.18	2,065	4,555,513	2,206.06
17	CYSTIC FIBROSIS CFTR CORRECTORS	203	5,295,448	26,085.95	-	-	-
18	ANTIDEPRESSANTS	165,095	4,838,493	29.31	413	439,410	1,063.95
19	WAKEFULNESS-PROMOTING AGENTS	2,310	3,579,206	1,549.44	76	986,136	12,975.47
20	ADRENALS	75,188	4,170,190	55.46	210	160,475	764.17

Drug Indicators by Highest Cost
Analysis of Formulary Distribution (continued)

<u>Rank</u>	<u>Indicator</u>	Formulary			Non-Formulary		
		<u>Number of Scripts</u>	<u>Ingredient Costs</u>	<u>Cost Per Script</u>	<u>Number of Scripts</u>	<u>Ingredient Costs</u>	<u>Cost Per Script</u>
21	GUANYLATE CYCLASE C - GCC RECEPT AGONIST	3,370	\$3,994,744	\$1,185.38	-	\$ -	\$ -
22	ANTIRETROVIRALS	1,812	3,492,938	1,927.67	16	53,492	3,343.28
23	VASODILATING AGENTS RESPIRATORY TRACT	190	2,669,409	14,049.52	30	824,961	27,498.70
24	ANTICHOLINERGIC AGENTS RESPIR TRACT	2,474	3,220,728	1,301.83	-	-	-
25	ANTI-INFLAMMATORY AGENTS EENT	1,692	2,917,572	1,724.33	88	98,371	1,117.86
26	ANGIOTENSIN II RECEP ANTAGONIST/NEPROLYS	1,840	2,892,256	1,571.88	-	-	-
27	AMPHETAMINES	31,744	2,320,682	73.11	1,406	512,893	364.79
28	HEMATOPOIETIC AGENTS	297	2,667,903	8,982.84	-	-	-
29	FUMARATES	320	2,446,931	7,646.66	11	98,665	8,969.55
30	PITUITARY	723	2,226,451	3,079.46	34	114,839	3,377.62
31	CONTRACEPTIVES	35,654	2,170,687	60.88	294	157,516	535.77
32	ANTIBACTERIALS MISCELLANEOUS	15,971	2,251,688	140.99	6	693	115.50
33	INTERLEUKIN ANTAGONISTS	451	1,970,283	4,368.70	10	234,780	23,477.95
34	MONOCLONAL ANTIBODIES - 90:04	261	2,188,991	8,386.94	-	-	-
35	DIGESTANTS	684	2,122,513	3,103.09	-	-	-
36	HMG-COA REDUCTASE INHIBITORS	86,709	2,078,389	23.97	17	7,066	415.66
37	PROTON-PUMP INHIBITORS	70,390	2,050,968	29.14	26	13,590	522.70
38	ANTICONVULSANTS MISCELLANEOUS	21,352	1,287,186	60.28	297	756,915	2,548.53
39	ANTIMUSCARINICS/ANTISPASMODICS	8,639	2,011,309	232.82	53	23,551	444.35
40	THYROID AGENTS	43,864	1,368,469	31.20	5,805	655,807	112.97
	<u>All Other</u>	<u>1,231,264</u>	<u>54,308,632</u>	<u>44.11</u>	<u>7,060</u>	<u>11,191,597</u>	<u>1,585.21</u>
	Total	1,988,643	\$435,178,967	\$218.83	19,397	\$27,809,001	\$1,433.68

Drug Indicators by Highest Number of Scripts Increase



Rank	Indicator	Formulary Cost Per Script	Non-Formulary Cost Per Script	Increase/ Decrease
1	INCRETIN MIMETICS	\$1,549.25	\$1,237.62	-20%
44	RESPIRATORY AND CNS STIMULANTS	58.73	504.47	759%
27	AMPHETAMINES	73.11	364.79	399%
38	ANTICONVULSANTS MISCELLANEOUS	60.28	2,548.53	4128%
85	OPIOID PARTIAL AGONISTS	67.12	228.26	240%
16	ANTIPSYCHOTIC AGENTS	57.18	2,206.06	3758%
10	CALCITONIN GENE-RELATED PEPTIDE ANTAG	1,133.84	1,049.49	-7%
109	ANDROGENS	58.26	252.36	333%
122	CELL STIMULANTS AND PROLIFERANTS	62.79	44.49	-29%
32	ANTIBACTERIALS MISCELLANEOUS	140.99	115.50	-18%
88	ANTIBACTERIALS EENT	30.96	343.91	1011%
42	PCSK9 INHIBITORS	808.53	616.65	-24%
113	CHOLESTEROL ABSORPTION INHIBITORS	40.58	-	-
84	MINERALOCORTICOID ALDOSTERONE ANTAGNTS	48.91	199.04	307%
5	SODIUM-GLUC COTRANSPORT 2 SGLT2 INHIB	1,468.86	1,307.85	-11%
9	SKIN AND MUCOUS MEMBRANE AGENTS MISC	2,895.59	305.26	-89%
76	ION CHANNEL INHIBITION AGENTS	95.99	1,542.75	1507%
48	ANGIOTENSIN II RECEPTOR ANTAGONISTS	31.10	621.91	1899%
19	WAKEFULNESS-PROMOTING AGENTS	1,549.44	12,975.47	737%
47	ESTROGENS	119.69	521.09	335%



Drug Indicators by Highest Number of Scripts Increase
(continued)


Rank	Indicator	Formulary Cost Per Script	Non-Formulary Cost Per Script	Increase/ Decrease
129	AZOLE ANTIFUNGALS	\$39.93	\$0.00	-
73	KERATOLYTIC AGENTS	277.80	556.42	100%
7	IMMUNOMODULATORY AGENTS - 84:06	9,710.94	9,988.59	3%
58	BETA-3-ADRENERGIC AGONISTS	955.19	1,014.42	6%
12	JANUS KINASE INHIBITORS - 90:24	6,209.87	3,988.57	-36%
24	ANTICHOLINERGIC AGENTS RESPIR TRACT	1,301.83	-	-
125	BETA-ADRENERGIC BLOCKING AGENTS	29.75	-	-
21	GUANYLATE CYCLASE C - GCC RECEPT AGONIST	1,185.38	-	-
117	OPIOID ANTAGONISTS - 28:10	156.14	116.49	-25%
26	ANGIOTENSIN II RECEPT ANTAGONIST/NEPROLYS	1,571.88	-	-
33	INTERLEUKIN ANTAGONISTS	4,368.70	23,477.95	437%
22	ANTIRETROVIRALS	1,927.67	3,343.28	73%
99	PROGESTINS	49.29	53.74	9%
4	INTERLEUKIN-MEDIATED AGENTS	13,006.25	6,889.54	-47%
127	ANTIMETABOLITES IMMUNOSUPPRESS THERAPY	81.82	648.11	692%
79	JANUS KINASE INHIBITORS - 84:06	6,131.49	2,167.94	-65%
60	INTERLEUKIN INHIBITOR AGENTS	2,405.26	-	-
130	URINARY ANTI-INFECTIVES	28.19	93.92	233%
28	HEMATOPOIETIC AGENTS	8,982.84	-	-
128	BASIC OINTMENTS AND PROTECTANTS	489.37	1,298.70	165%

Drugs by Highest Cost
Analysis of Formulary Distribution

<u>Rank</u>	<u>Drug</u>	Formulary			Non-Formulary		
		<u>Number of Scripts</u>	<u>Ingredient Costs</u>	<u>Cost Per Script</u>	<u>Number of Scripts</u>	<u>Ingredient Costs</u>	<u>Cost Per Script</u>
1	OZEMPIC	25,361	\$37,762,247	\$1,488.99	-	-	-
2	MOUNJARO	23,462	33,294,931	1,419.10	-	-	-
3	HUMIRA(CF) PEN	3,903	31,988,616	8,195.90	-	-	-
4	STELARA	638	15,450,862	24,217.65	-	-	-
5	JARDIANCE	7,382	11,070,655	1,499.68	-	-	-
6	TRULICITY	4,865	9,670,268	1,987.72	-	-	-
7	SKYRIZI PEN	462	9,265,149	20,054.43	-	-	-
8	FARXIGA	5,804	8,344,887	1,437.78	-	-	-
9	TREMFYA	572	7,563,887	13,223.58	-	-	-
10	WEGOVY	2,632	6,280,062	2,386.04	-	-	-
11	TALTZ AUTOINJECTOR	916	6,120,159	6,681.40	-	-	-
12	OTEZLA	1,202	5,466,523	4,547.86	-	-	-
13	TRIKAFTA	203	5,295,448	26,085.95	-	-	-
14	DUPIXENT PEN	1,408	5,273,378	3,745.30	-	-	-
15	XARELTO	3,811	5,243,710	1,375.94	-	-	-
16	RINVOQ	751	5,064,404	6,743.55	-	-	-
17	JANUVIA	3,495	4,900,556	1,402.16	-	-	-
18	ENBREL SURECLICK	711	4,790,719	6,738.00	-	-	-
19	TRESIBA FLEXTOUCH U-200	2,453	4,646,625	1,894.26	-	-	-
20	ELIQUIS	3,360	4,282,218	1,274.47	-	-	-
	<u>All Other</u>	1,895,252	213,403,664	112.60	19,397	27,809,001	1,433.68
	Total	1,988,643	\$435,178,967	\$218.83	19,397	\$27,809,001	\$1,433.68







1 – Incretin Mimetics

In FY 2024, the Incretin Mimetics Drugs category was first in cost to PEIA with expenditure of \$95,309,184, which accounted for 20.6% of total expenditures. Formulary expenditures were \$95,133,442 or 99.8% of Incretin Mimetics expenditures and total expenditures had a 49.3% trend from 2023 to 2024.

Drug	Formulary Indicator	Current Brand/ Generic	Number of Prescriptions			Ingredient Cost Per Prescription			Total Ingredient Cost		
			2023	2024	Growth	2023	2024	Growth	2023	2024	Growth
OZEMPIC	Yes	SSB	20,653	25,361	22.8%	\$1,570	\$1,489	-5.2%	\$32,426,097	\$37,762,247	16.5%
MOUNJARO	Yes	SSB	8,167	23,462	187.3%	1,276	1,419	11.2%	10,424,899	33,294,931	219.4%
TRULICITY	Yes	SSB	7,908	4,865	-38.5%	1,885	1,988	5.4%	14,906,653	9,670,268	-35.1%
WEGOVY	Yes	SSB	1,900	2,632	38.5%	1,662	2,386	43.5%	3,158,269	6,280,062	98.8%
ZEPBOUND	Yes	SSB	0	2,936	NA	NA	1,419	NA	0	4,167,250	NA
<u>Subtotals</u>											
Generic	Y	GEN	0	0	NA	NA	NA	NA	\$0	\$0	NA
Formulary Brand	Y	Brand	40,694	61,406	50.9%	\$1,586	\$1,549.25	-2.3%	64,553,050	95,133,442	47.4%
<u>Non-Formulary Brand</u>	<u>N</u>	<u>Brand</u>	<u>141</u>	<u>142</u>	<u>0.7%</u>	<u>1,535</u>	<u>1,238</u>	<u>-19.4%</u>	<u>216,386</u>	<u>175,742</u>	<u>-18.8%</u>
Total			40,835	61,548	50.7%	\$1,586	\$1,549	-2.4%	\$64,769,436	\$95,309,184	47.2%
Trends Adjusted for Exposure					53.0%			-2.4%			49.3%

2 – Antineoplastic Agents

In FY 2024, the Antineoplastic Agents category was second in cost to PEIA with expenditure of \$32,190,194, which accounted for 7.0% of total expenditures overall. Formulary expenditures were \$29,060,022 or 90.3% of Antineoplastic Agent expenditures and total ingredient cost had a 16.7% trend from 2023 to 2024.

Drug	Formulary Indicator	Current Brand/ Generic	Number of Prescriptions			Ingredient Cost Per Prescription			Total Ingredient Cost		
			2023	2024	Growth	2023	2024	Growth	2023	2024	Growth
REVLIMID	Yes	SSB	199	162	-18.6%	\$16,276.46	\$17,516.62	7.6%	\$3,239,015	\$2,837,692	-12.4%
SPRYCEL	Yes	SSB	203	175	-13.8%	14,212.34	15,622.72	9.9%	2,885,105	2,733,977	-5.2%
VERZENIO	Yes	SSB	122	188	54.1%	12,533.91	13,774.24	9.9%	1,529,137	2,589,556	69.3%
LENALIDOMIDE	Yes	GEN	54	118	118.5%	13,944.70	15,328.82	9.9%	753,014	1,808,801	140.2%
XTANDI	Yes	SSB	90	127	41.1%	12,914.39	13,581.18	5.2%	1,162,295	1,724,810	48.4%
<u>Subtotals</u>											
Generic	Y	GEN	7,316	7,213	-1.4%	\$464	\$612	31.9%	\$3,396,468	\$4,417,418	30.1%
Formulary Brand	Y	Brand	1,476	1,629	10.4%	14,474	15,127	4.5%	21,363,169	24,642,603	15.4%
<u>Non-Formulary Brand</u>	<u>N</u>	<u>Brand</u>	<u>208</u>	<u>217</u>	<u>4.3%</u>	<u>13,624</u>	<u>14,425</u>	<u>5.9%</u>	<u>2,833,725</u>	<u>3,130,172</u>	<u>10.5%</u>
Total			9,000	9,059	0.7%	\$3,066	\$3,553	15.9%	\$27,593,362	\$32,190,194	16.7%
Trends Adjusted for Exposure					0.7%			15.9%			16.7%

3 – Antirheumatic Agents

In FY 2024, the Antirheumatic Agents indicator category was third in cost to PEIA with expenditure of \$30,021,039, which accounted for 6.5% of total expenditures. Formulary expenditures were \$30,021,039 or 100.0% of Antirheumatic Agent expenditures. Total expenditures had a 5.9% trend from 2023 to 2024.

Drug	Formulary Indicator	Current Brand/ Generic	Number of Prescriptions			Ingredient Cost Per Prescription			Total Ingredient Cost		
			2023	2024	Growth	2023	2024	Growth	2023	2024	Growth
HUMIRA(CF) PEN	Yes	SSB	3,640	3,592	-1.3%	\$7,223	\$7,709	6.7%	\$26,292,343	\$27,689,012	5.3%
HUMIRA(CF)	Yes	SSB	266	258	-3.0%	7,803	8,352	7.0%	2,075,636	2,154,699	3.8%
CYLTEZO(CF) PEN	Yes	SSB	0	19	NA	NA	9,333.08	NA	0	177,328	NA
N/A	-	-	-	-	-	-	-	-	-	-	-
N/A	-	-	-	-	-	-	-	-	-	-	-
<u>Subtotals</u>											
Generic	Y	GEN	5	0	-100.0%	\$16.12	NA	NA	\$81	\$0	-100.0%
Formulary Brand	Y	Brand	3,906	3,869	-0.9%	7,263	7,759	6.8%	28,367,978	30,021,039	5.8%
<u>Non-Formulary Brand</u>	<u>N</u>	<u>Brand</u>	<u>0</u>	<u>0</u>	<u>NA</u>	<u>NA</u>	<u>NA</u>	<u>NA</u>	<u>0</u>	<u>0</u>	<u>NA</u>
Total			3,911	3,869	-1.1%	\$7,253	\$7,759	7.0%	\$28,368,059	\$30,021,039	5.8%
Trends Adjusted for Exposure					-1.0%			7.0%			5.9%

4 – Interleukin-Mediated Agents

In FY 2024, the Interleukin-Mediated Agents indicator category was fourth in cost to PEIA with expenditure of \$26,030,827, which accounted for 5.6% of total expenditures. Formulary expenditures were \$23,385,244 or 89.8% of Interleukin-Mediated Agent expenditures. Total expenditures had a 19.7% trend from 2023 to 2024.

Drug	Formulary Indicator	Current Brand/ Generic	Number of Prescriptions			Ingredient Cost Per Prescription			Total Ingredient Cost		
			2023	2024	Growth	2023	2024	Growth	2023	2024	Growth
STELARA	Yes	SSB	559	638	14.1%	\$22,476	\$24,218	7.7%	\$12,564,255	\$15,450,862	23.0%
TALTZ AUTOINJECTOR	Yes	SSB	817	916	12.1%	6,369	6,681	4.9%	5,203,546	6,120,159	17.6%
COSENTYX (2 PENS)	No	SSB	240	167	-30.4%	6,531	7,633	16.9%	1,567,376	1,274,719	-18.7%
TALTZ (2 PACK)	Yes	SSB	59	60	1.7%	12,419	13,172	6.1%	732,737	790,349	7.9%
COSENTYX PEN	No	SSB	64	75	17.2%	6,210	7,436	19.7%	397,436	557,716	40.3%
<u>Subtotals</u>											
Generic	Y	GEN	0	0	NA	NA	NA	NA	0	0	NA
Formulary Brand	Y	Brand	1,587	1,798	13.3%	12,158	13,006	7.0%	19,294,324	23,385,244	21.2%
<u>Non-Formulary Brand</u>	<u>N</u>	<u>Brand</u>	414	384	<u>-7.2%</u>	<u>6,124</u>	<u>6,890</u>	<u>12.5%</u>	<u>2,535,373</u>	<u>2,645,582</u>	<u>4.3%</u>
Total			2,001	2,182	9.0%	\$10,909	\$11,930	9.4%	\$21,829,698	\$26,030,827	19.2%
Trends Adjusted for Exposure					9.4%			9.4%			19.7%

5 –Sodium Glucose Cotransporters

In FY 2024, the Sodium Glucose Cotransport indicator category was fifth in cost to PEIA with expenditure of \$20,634,558, which accounted for 4.5% of total expenditures. Formulary expenditures were \$20,527,315 or 99.5% of Sodium Glucose Cotransport expenditures. Total expenditures had a 10.2% trend from 2023 to 2024.

Drug	Formulary Indicator	Current Brand/ Generic	Number of Prescriptions			Ingredient Cost Per Prescription			Total Ingredient Cost		
			2023	2024	Growth	2023	2024	Growth	2023	2024	Growth
JARDIANCE	Yes	SSB	6,715	7,382	9.9%	\$1,412	\$1,500	6.2%	\$9,482,767	\$11,070,655	16.7%
FARXIGA	Yes	SSB	5,849	5,804	-0.8%	1,383	1,438	3.9%	8,090,212	8,344,887	3.1%
XIGDUO XR	Yes	SSB	384	354	-7.8%	1,296	1,313	1.3%	497,630	464,777	-6.6%
SYNJARDY XR	Yes	SSB	181	354	95.6%	1,373	1,313	-4.4%	248,563	464,777	87.0%
GLYXAMBI	Yes	SSB	109	179	64.2%	1,507	1,497	-0.6%	164,261	268,000	63.2%
<u>Subtotals</u>											
Generic	Y	GEN	0	0	NA	NA	NA	NA	\$0	\$0	NA
Formulary Brand	Y	Brand	13,454	13,975	3.9%	1,395	1,469	5.3%	18,762,786	20,527,315	9.4%
<u>Non-Formulary Brand</u>	<u>N</u>	<u>Brand</u>	5	82	<u>1540.0%</u>	<u>757</u>	<u>1,308</u>	<u>72.7%</u>	<u>3,787</u>	<u>107,243</u>	<u>2732.2%</u>
<u>Total</u>			13,459	14,057	4.4%	\$1,394	\$1,468	5.3%	\$18,766,572	\$20,634,558	10.0%
Trends Adjusted for Exposure					4.6%			5.3%			10.2%